

# UC Irvine

## UC Irvine Previously Published Works

### Title

Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation

### Permalink

<https://escholarship.org/uc/item/1661d5rb>

### Journal

Journal of Molecular Biology, 431(9)

### ISSN

0022-2836

### Authors

Huat, Tee Jong  
Camats-Perna, Judith  
Newcombe, Estella A  
[et al.](#)

### Publication Date

2019-04-01

### DOI

10.1016/j.jmb.2019.01.018

Peer reviewed



# HHS Public Access

Author manuscript

*J Mol Biol.* Author manuscript; available in PMC 2020 April 19.

Published in final edited form as:

*J Mol Biol.* 2019 April 19; 431(9): 1843–1868. doi:10.1016/j.jmb.2019.01.018.

## Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation

Tee Jong Huat<sup>1,2,\*</sup>, Judith Camats-Perna<sup>1</sup>, Estella A. Newcombe<sup>1</sup>, Nicholas Valmas<sup>3</sup>, Masashi Kitazawa<sup>4</sup>, and Rodrigo Medeiros<sup>1,\*</sup>

<sup>1</sup>Neurula Laboratory, Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Australia.

<sup>2</sup>Centre for Stem Cell Ageing and Regenerative Engineering, The University of Queensland, Australia.

<sup>3</sup>Queensland Brain Institute, The University of Queensland, Australia.

<sup>4</sup>Center for Occupational and Environmental Health, Department of Medicine, University of California, Irvine, CA, USA.

### Abstract

As the median age of the population increases, the number of individuals with Alzheimer's disease (AD) and the associated socio-economic burden are predicted to worsen. While aging and inherent genetic predisposition play major roles in the onset of AD, lifestyle, physical fitness, medical condition, and social environment have emerged as relevant disease modifiers. These environmental risk factors can play a key role in accelerating or decelerating disease onset and progression. Among known environmental risk factors, chronic exposure to various metals has become more common among the public as the aggressive pace of anthropogenic activities releases excess amount of metals into the environment. As a result, we are exposed not only to essential metals, such as iron, copper, zinc and manganese, but also to toxic metals including lead, aluminum, and cadmium, which perturb metal homeostasis at the cellular and organismal levels. Herein, we review how these metals affect brain physiology and immunity, as well as their roles in the accumulation of toxic AD proteinaceous species (*i.e.*,  $\beta$ -amyloid and tau). We also discuss studies that validate the disruption of immune-related pathways as an important mechanism of toxicity by which metals can contribute to AD. Our goal is to increase the awareness of metals as players in the onset and progression of AD.

### Keywords

Environment; dementia;  $\beta$ -amyloid; tau; neurodegeneration

---

\*Corresponding Authors: Rodrigo Medeiros, Ph.D., rodrigo.medeiros@neurula.org or r.medeiros@uq.edu.au. Tee Jong Huat, Ph.D., t.tee@uq.edu.au, Address: Queensland Brain Institute, The University of Queensland, Brisbane, 4072, Australia. Phone: +61734431104.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder that leads to cognitive impairment and dementia in the elderly. Fifty million people worldwide were living with dementia in 2018, and this number is expected to more than triple to 152 million by 2050, with AD accounting for an estimated 60–80% of these [1]. The reasons that cause individuals to be sensitive or resilient to AD are still elusive. Although mutations in the  $\beta$ -amyloid ( $A\beta$ )-related genes *app*, *psen1* and *psen2* are known to cause AD, these mutations account for less than 1% of total AD cases (Fig. 1). Recent genetic studies have improved our understanding of the factors that make some people prone to AD by identifying genetic variants that cause a slight to moderate increase in risk (*e.g.*, *apoe*, *trem2*, *cd33*). These genetic studies have also revealed a broader picture of the processes and pathways involved in AD. It is now accepted that changes in lipid metabolism, endocytosis and inflammatory responses can contribute to the onset and progression of the disease. Lifestyle factors also affect an individual's risk of developing AD, many of which are potentially modifiable, including dietary habits and exposure to environmental and occupational hazards [2, 3].

Neuropathologically, AD is characterized by the misfolding and aggregation of two key proteins in the brain,  $A\beta$  and tau, leading to the formation of plaques and neurofibrillary tangles (NFTs), respectively (Fig. 1). The formation of plaques is preceded by the production of  $A\beta$ , caused by changes in amyloid precursor protein (APP) processing, with NFTs forming due to abnormal hyperphosphorylation of tau. APP is abundant in the healthy brain, where it is cleaved by  $\alpha$ -secretase to produce the non-pathogenic protein fragment soluble APP $\alpha$  [4]. However, in the AD brain, APP cleavage by  $\beta$ - and  $\gamma$ -secretase leads to the production of toxic  $A\beta$  fragments. These are prone to misfolding and forming oligomers, which are considered the most toxic  $A\beta$  species. Although it has been demonstrated that  $A\beta$  production and misfolding occur prior to any of the other pathologies associated with AD, the trigger(s) for this remains to be fully identified [5]. The production of  $A\beta$  has been shown to lead to the hyperphosphorylation of the microtubule-associated tau protein, stimulated by the phosphorylation of the tau kinases glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ), cyclin-dependent kinase 5 (CDK5) and extracellular signal-regulated kinase 1/2 (ERK1/2) [6, 7]. The hyperphosphorylation of tau can cause microtubule destabilization and breakdown, perturb axonal transport, and make tau far more prone to aggregation into NFTs [8–10]. NFT load correlates with cognitive impairment and neurodegeneration, leading to the suggestion that reducing tau hyperphosphorylation and NFT formation are key to preventing AD [11, 12].

The brain has mechanisms to clear toxic proteins, including degradation pathways and the immune system. Inflammation poses a key risk for AD with respect to both genetic (*e.g.*, *apoe*, *trem2*, *cd33*) and lifestyle factors (*e.g.*, diabetes mellitus, obesity, traumatic brain injury) [3]. With respect to the proteins involved in AD, both  $A\beta$  and tau can be altered by neuroinflammation. Accumulation of  $A\beta$  triggers a proinflammatory response from the brain's resident immune cells, microglia and astrocytes, leading to the phagocytosis of plaques as well as their proteolytic degradation. Receptors on microglia, such as triggering receptor expressed on myeloid cells 2 (TREM2) and toll-like receptors (TLRs), can recognize  $A\beta$  and trigger a phagocytic pathway [13, 14].  $A\beta$  degrading enzymes, including neprilysin and insulin degrading enzyme, can also be released to remove  $A\beta$  extracellularly,

although the activity of these enzymes is reduced in AD [15, 16]. Moreover, the exacerbated proinflammatory state that occurs during this period of the disease can trigger the hyperphosphorylation of tau. Several of the kinases responsible for tau phosphorylation are activated by proinflammatory mediators and have been shown to worsen tau pathology [17, 18]. Interestingly, microglial uptake of hyperphosphorylated tau is linked to the propagation of tau pathology, and the overactivation of proinflammatory microglia by A $\beta$  may therefore lead to worsened tauopathy [19]. Microglia become senescent over the progression of AD [20, 21], in part due to the excessive production of A $\beta$ . During this phenotypic state, they continue to produce microglia-recruiting, proinflammatory mediators, including cytokines and chemokines, causing more microglia eventually becoming senescent [22]. Not only can this exacerbate A $\beta$  and tau pathology, but microglia can become overactive in neurodegeneration, excessively pruning synapses and injuring neurons [23].

Among the chemical elements of relevance to humans, metals play a significant role in both health and disease. Metals are natural constituents of the Earth's crust and are disseminated into the biosphere through human activities [24, 25]. These compounds display high stability, solubility in atmospheric precipitation, and ability to be absorbed by soil and living organisms, with human exposure soaring because of an exponential increase in their use in several industrial, agricultural, domestic and technological applications. Common sources of metals are mining, tailings, industrial waste, agricultural runoff, paints, treated timber, aging water supply infrastructure, vehicle emissions, lead-acid batteries, fertilizers and microplastics. The main routes of human exposure include ingestion, inhalation and dermal contact [25]. Physiologically, some metals are either essential nutrients (*e.g.*, iron and zinc) or relatively harmless (*e.g.*, ruthenium, silver, and indium), but even these can be toxic in larger amounts or certain forms (Fig. 2). This is because metals are usually essential components of larger biological molecules that can interact with or regulate the levels of relatively large numbers of other molecules [26]. This means that the optimal physiological concentration range between deficiency and toxicity of metals is relatively small and needs to be tightly controlled. Importantly, tiny amounts of non-essential metals also promote severe toxicity as they inadvertently disrupt the physiological activity of essential metals. Because of their high degree of toxicity, cadmium, lead and aluminum rank among the priority metals that are of public health significance (Fig. 2). These metallic elements are considered systemic toxicants that are known to induce multiple organ damage, even at lower levels of exposure. Notably, evidence suggests that dysregulation in the homeostasis of essential metals (Fig. 3) and exposure to non-essential metals (Fig. 4) have significant impact on the pathogenesis of AD. In the next part of this review we will discuss the impact that some of these trace metals exert in the brain, and how they contribute to AD and the dysregulation of the immune system.

## The essential metals

### Iron (Fe)

Besides its role in oxygen homeostasis, iron orchestrates a broad range of cellular functions, such as respiration, energy metabolism, DNA synthesis and repair, and signaling [27]. Other roles of iron in the central nervous system (CNS), include its participation in the myelination

of the spinal cord and white matter, and in the synthesis, packaging, uptake and degradation of neurotransmitters. Ironically, iron's ability to undergo oxidation-reduction reactions, which is the property that makes it biologically valuable, also allows it to convert hydrogen peroxide into a highly toxic hydroxyl free radical. Through the production of these reactive oxygen species (ROS), iron can induce severe brain damage. The systemic and cellular mechanisms that control iron intake, storage, utilization, and recycling are therefore strictly regulated. A recent computational study has established that the iron metabolic network consists of 151 chemical species, 107 reactions and transport steps [28]. In the brain, this network involves multiple transporter proteins that regulate the traffic of iron across different tissues and cells, including transferrin receptor 1, divalent metal transporter 1 (DMT1), lactoferrin, melanotransferrin and ferroportin [29]. Once within the cells, iron can follow different pathways depending on cellular need. Ultimately, control of the intracellular metabolism of iron occurs through iron-regulatory proteins (IRP) that bind iron-responsive elements (IRE) in regulated mRNAs [30]. Notably, disruptions of iron brain homeostasis have been linked to several diseases. While brain iron deficiency results in unfavorable pregnancy outcomes and cognitive developmental defects in children, such as attention deficit hyperactivity disorder [31], its excessive accumulation in adults has been linked to neurodegenerative diseases, including AD [32–34]. Changes in iron levels in AD can be detected as early as the mild cognitive impairment stage of the disease [35]. For this reason, iron-based magnetic resonance imaging contrast, which can detect iron content in the brain, has been investigated as a potential imaging biomarker due to its capacity to discriminate pathological changes related to AD [36–39]. Recent evidence has demonstrated that cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying AD pathology [40]. Together, these studies indicate that changes in iron metabolism may facilitate disease progression in the prodromal stages, which could be used as a biomarker of AD.

Over the years, many studies have helped to mechanistically link iron metabolism and AD. For instance, APP mRNA encodes a functional IRE in its 5'-untranslated region that binds with IRP-1, and its translation is down-regulated in response to intracellular iron chelation [41, 42]. At the protein level, APP acts as a modulator of iron function, as it oxidizes  $\text{Fe}^{2+}$ , loads  $\text{Fe}^{3+}$  into transferrin, and interacts with the iron transporter ferroportin. *In vitro* studies have shown that ablation of APP induces marked iron retention in cells, whereas APP overexpression promotes iron export. Likewise, genetic deletion of APP in mice causes iron accumulation and oxidative stress in cortical neurons, making animals vulnerable to dietary iron exposure compared to normal mice [43]. Moreover, several of the biological abnormalities seen in AD are consistent with an excessive action of oxygenic free radicals caused by impairment in iron homeostasis, and  $\text{A}\beta$  plaques and NFTs are major sites for catalytic redox reactivity [44, 45]. Iron and its regulatory proteins ferritin (iron storage) and transferrin (iron mobilization) are largely found in oligodendrocytes in physiological conditions. In AD, however, substantial amounts of iron and ferritin are detected within plaques, NFTs and blood vessels [46, 47, 45]. Although iron- and ferritin-positive oligodendrocytes are present, most of the iron- and ferritin-containing cells associated with the markers of AD are microglia [48–51]. Likewise, transferrin is distributed extracellularly around plaques and in astrocytes in the AD brain rather than its normal distribution in

oligodendrocytes [48]. It has been suggested that microglia and astrocytes accumulate higher iron content in AD because they are more resistant to oxidative stress than neuronal cells [52]. Despite this, the accumulation of iron in these glial cells does seem to compromise their function [53]. Other components of the iron network are also altered in AD, including lactotransferrin [54, 55], melanotransferrin [56], and IRP-2 [57]. Changes in iron metabolism are therefore prominent in AD at the cellular level. However, how these changes affect the function of the distinct brain cells and their communication, remain to be fully elucidated.

A large part of iron's detrimental effect in the AD is related to its cytotoxic redox properties, which are further impaired during the progression of the disease. In a mouse model, the neurological impairment induced by the infusion of A $\beta$  peptide was exacerbated by the genetic deletion of mitochondrial ferritin, a process that was associated with an accumulation of intracellular iron and increased levels of oxidative stress [58]. *In vitro* studies have demonstrated that the affinity of A $\beta$  for iron increases following its aggregation, and that this binding potentiates A $\beta$  neuronal toxicity [59–62]. This occurs because the binding between iron and A $\beta$  modulates the redox potential to a level at which iron's redox cycling occurs, resulting not only in the generation of oxidative species, but also the depletion of essential oxygen and biological reductants. By binding to iron, A $\beta$  also competes against other essential iron-containing proteins. For example, the affinity of A $\beta$  for iron is eight orders of magnitude stronger than that of transferrin, and its accumulation can therefore change the iron homeostasis [63]. In agreement with this idea, it has been shown that A $\beta$  deposition in the APP/PS1 mouse model is accompanied by changes in iron-related proteins, DMT1 and ferroportin 1 (FPN1), whose levels in the brain are increased and reduced, respectively [64]. Of note, DMT1 relocates to cellular and endosomal membranes, where it is a key player in non-transferrin bound iron uptake and transferrin-bound iron uptake, respectively [65]. FPN1, on the other hand, plays an essential role in the export of iron from cells to the blood [66]. Interestingly, *in vitro* studies have demonstrated that silencing of endogenous DMT1 not only reduces iron influx but also leads to reductions in APP expression and A $\beta$  production [67–69]. Pharmacological inhibition of DMT1 also seems to reduce iron-induced tau pathology in human neuroblastoma SH-SY5Y cells, through the inhibition of the tau kinases CDK5 and GSK-3 $\beta$  [70]. Importantly, other studies have demonstrated the capacity of iron to interfere with markers of AD pathology, as *in vitro* and *in vivo* data show that iron overload results in higher A $\beta$  production, neuronal toxicity and cognitive impairment [71, 72]. Another relevant study in the APP/PS1 mouse model revealed that the iron chelating agent deferoxamine inhibits A $\beta$  accumulation and improves cognitive function. It was proposed that this effect is dependent on the alternative activation of microglia, which become more prone to clear A $\beta$  via phagocytosis [73]. This hypothesis, however, needs further validation as many agents that reduce A $\beta$  deposition in mice can indirectly improve microglial and cognitive functions.

With regards to changes in the brain immune system, microglial dystrophy in the aged and AD brains is associated with ferritin immunoreactivity [53]. Disruption of iron homeostasis through brain hemorrhage also enhances microgliosis and astrogliosis, and results in elevated levels of the proinflammatory cytokines tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-1 $\beta$  (IL-1 $\beta$ ) [74]. This is particularly interesting since traumatic brain injury is a potential risk factor for AD [3]. Excess iron has also been shown to activate microglia by

inducing the nuclear factor- $\kappa$ B (NF- $\kappa$ B)-mediated transcription of proinflammatory cytokines [75, 76]. Interestingly, the accumulation of inflammatory signals, such as TNF- $\alpha$  and IL-6, triggers the upregulation of DMT1 and downregulation of ferroportin, suggesting that the mechanism for iron accumulation into neurons and microglia during inflammation is in part due to changes in the levels of iron transporters [77]. Iron accumulation in macrophages and microglia following CNS damage has also been linked to a shift in cell activation towards a proinflammatory phenotype, which results in lower phagocytic efficiency [78]. Although these studies suggest that a positive feedback loop between iron accumulation and excessive proinflammation progressively contributes to neurotoxicity, they failed to provide a clear molecular mechanism by which iron contributes to the function of glial cells. Particularly, it would be important to determine whether iron metabolism directly regulates functions of microglia and astrocytes, like immune surveillance and synaptic pruning, during homeostasis and disease states.

### Copper (Cu)

Like iron, copper is a highly desirable chemical element in cell biology due to its ability to gain and donate electrons. Once taken up and distributed in an organism, copper ions cycle between cupric  $\text{Cu}^{2+}$  (oxidized) and cuprous  $\text{Cu}^+$  (reduced) states, mostly bound to cuproenzymes with only a small portion available as labile copper, also known as free or unbound copper [79]. This redox property is essential for catalysis by many enzymes whose activities control a broad range of cellular biochemical and regulatory functions. The relevance of copper for human health is easily emphasized by two life-threatening disorders caused by mutations in P-type  $\text{Cu}^+$ -transporting ATPase pumps: Menkes and Wilson's diseases [80]. Menkes disease is an X-linked lethal disorder of intestinal copper hyperaccumulation, and severe copper deficiency in peripheral and central tissues. It is caused by loss-of-function mutations in the ATP7A protein, which results in infantile-onset cerebral and cerebellar neurodegeneration due to a failure in copper transport into the CNS [81]. The neuronal damage caused by the failure in copper homeostasis is attributed to its many roles in processes essential for normal brain function, including the synthesis of catecholamines, activation of neuropeptides and hormones, antioxidant defense, connective tissue production, immune function and synaptic transmission [82–84]. Wilson's disease, on the other hand, is an autosomal recessive disease caused by mutations in the ATP7B protein, a transporter that loads  $\text{Cu}^+$  onto newly synthesized cuproenzymes in the trans-Golgi network (TGN) and exports excess copper out of cells by trafficking from the TGN to the plasma membrane. The disease is characterized by striking hepatic and neuronal copper overload, hepatotoxicity, and neuropsychological and other defects that require chronic therapy to enhance copper excretion or reduce its absorption [85]. Remarkably, this disease highlights the fact that copper's greatest strength is also its major weakness as excess causes it to participate in redox reactions that generate ROS, leading to catastrophic damage to lipids, proteins and DNA. Therefore, intracellular levels of copper must be tightly regulated as excessive free copper is highly toxic [79].

Considering the robust evidence for copper's essential roles in the brain, it is not surprising that many studies have proposed that an imbalance in its homeostasis is associated with neurodegenerative disorders. Besides AD, copper has been linked to amyotrophic lateral

sclerosis, Parkinson's disease, Huntington's disease and prion-mediated encephalopathies [86–90]. In AD, it has been suggested that individuals suffering from the disease have higher serum levels of copper than healthy controls, with higher levels of labile copper in the serum correlating with poor cognitive performance and increased rates of conversion from mild cognitive impairment to AD [91–93]. Analyses of post-mortem human brains have revealed that the overall soluble levels of copper are reduced, whereas its presence within insoluble neuritic plaques is increased, in AD versus non-demented individuals [94–96]. Notably, despite a lower total copper content, AD brains possess a higher proportion of redox-active exchangeable copper, which positively correlates with increased oxidative damage and AD neuropathology [97].

Biochemical analyses have identified two binding sites for copper in full-length APP, including one within the A $\beta$  sequence. Binding of Cu<sup>2+</sup> to the N-terminal domain of APP results in its reduction to Cu<sup>+</sup> [98]. Genetic studies in mouse models have demonstrated that the APP-induced conversion of Cu<sup>2+</sup> to Cu<sup>+</sup> favors copper removal from the brain, which could explain the fact that AD patients have lower levels of copper in their brain and higher levels in their serum [99, 96, 91–93, 100]. Binding of copper to the N-terminus of APP may also control other aspects of this protein, including its synaptogenic function, stability and metabolism [101–105]. Interestingly, reduction in the level of brain copper increases the ratio of APP endocytosis and processing, and the production of A $\beta$ , perhaps as a protective mechanism to reverse the excessive loss of copper [101, 103]. However, newly synthesized intracellular A $\beta$  can sequester copper, which possibly serves to initially exacerbate the imbalance in copper levels and then later enable the aggregation of A $\beta$  into plaques. Such a process is highly relevant in the formation of neuritic plaques in AD because copper can potentiate A $\beta$  aggregation and cell damage due to the generation of ROS [106–108]. The protein tau has also been shown to bind copper, which facilitates the formation of NFTs [109–111]. Likewise, tau demonstrates redox activity when bound to copper, further contributing to the oxidative damage in the brain [112]. Considering the significance of tau in AD, it is surprising that only a small proportion of studies has investigated how changes in copper homeostasis affect its function. Future studies assessing whether copper regulates tau kinases and phosphatases as well as tau-mediated cognitive impairment are needed, and will greatly increase our understanding of the neuropathology of AD.

In relation to neuroinflammation, copper seems to play important roles modulating microglial activation, although there is limited evidence that it directly initiates the inflammatory process. It has been demonstrated that copper enhances the effect of A $\beta$  on microglial activation and subsequent neurotoxicity. Copper-A $\beta$  complexes induce microglial activation and the release of TNF- $\alpha$  and nitric oxide in an NF- $\kappa$ B-dependent manner. Interestingly, the effects produced by these complexes are not observed upon treatment with either copper or A $\beta$  alone [113, 114]. Recently, we have demonstrated that exposure to copper-A $\beta$  reduces the phagocytic phenotype of BV2 microglia and increases TNF- $\alpha$  and IL-1 $\beta$  release, followed by significant down-regulation of lipoprotein receptor-related protein-1 (LRP-1) expression [115]. Reduced levels of LRP-1 further impair the transcytotic clearance of A $\beta$  and exacerbate neuroinflammation [3]. It has been reported that trace copper potentiates the A $\beta$ -induced inflammatory response in cholesterol-fed mice; however, no inflammatory effects were observed upon treatment with copper or cholesterol alone [116].



These studies highlight the role of copper as a cofactor in increasing the potency of A $\beta$  toxicity with a subsequent contribution to microglial activation. Histological data have demonstrated that activated microglia express ATP7A specifically clustered around plaques. This ATP7A expression was found to be increased by the proinflammatory cytokine interferon- $\gamma$ , but not by TNF- $\alpha$  or IL-1 $\beta$  [117]. The inflammatory response associated with AD therefore seems to cause changes in microglial copper trafficking, which may underlie the changes in copper homeostasis in the disease. Remarkably, mice fed a copper-deficient diet display signs of microglial and astrocytic activation, suggesting that copper homeostasis is required physiologically to prevent neuroinflammation [118]. It has been proposed that copper homeostasis regulates the shift between proinflammatory and anti-inflammatory phenotypes in microglia via the regulation of nitric oxide levels and disruption of S-nitrosothiol signaling [119, 120]. Further understanding of the underlying mechanism by which copper regulates immune responses in the brain, particularly its role in the regulation of clearance of pathological forms of A $\beta$  and tau, may provide novel therapeutic opportunities for AD.

Different strategies have been used to prevent the pathogenic effects caused by an imbalance in copper homeostasis, including administration of metal chelators that redistribute brain metal pools and reverse A $\beta$  plaque aggregation [121–126]. Alternatively, reestablishing the proper intracellular bioavailable copper reduces secreted A $\beta$  levels via a mechanism that is dependent on the activation of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and c-Jun N-terminal kinase [127]. Likewise, it has recently been shown that increased intracellular copper inhibits A $\beta$  production by directly targeting the subunits PSEN and nicastrin in the  $\gamma$ -secretase complex [128]. Increasing intracellular copper bioavailability can also restore cognitive function by inhibiting the accumulation of neurotoxic A $\beta$  and phosphorylated tau [129]. Furthermore, there is evidence that the immunomodulatory potential of systemic copper bis(thiosemicarbazones), which are stable, lipophilic neutral Cu<sup>2+</sup> complexes that are capable of crossing cell membranes and the blood-brain barrier. This compound can inhibit microglial and astrocytic activation, and reducing the acute cerebrovascular inflammation caused by bacterial lipopolysaccharide [130]. Based on the evidence above, it would be expected that increasing copper levels in the body would restore its homeostasis in the brain. Unfortunately, systemic administration of copper promotes detrimental effects in AD by reducing A $\beta$  clearance. For instance, trace levels of copper in drinking water has been associated with higher A $\beta$  levels in the brain of distinct animal models [131, 132], a process that seems to be related to the dysfunction of LRP-1-mediated A $\beta$  clearance through the vasculature [133]. In addition to its effect on A $\beta$ , chronic systemic copper exposure exacerbates tau pathology, promotes cognitive impairment, and dysregulates the tau-related kinase CDK5 and the synaptic-related proteins complexin-1 and complexin-2, in a mouse model of AD [134, 135]. Taken altogether, these studies indicate that systemic copper promotes AD and therefore controlled copper diets should be considered. Despite the challenges, mitigating dysregulation in copper homeostasis in the brain clearly has great benefits and should be further explored as a therapeutic strategy for AD.

## Zinc (Zn)

The brain contains the highest zinc concentrations of any organ in the body. Seventy percent of proteins present in the brain contain zinc as a structural or catalytic component, contributing to the efficient performance of over 2,000 transcription factors and more than 300 enzymes [136]. The transport of zinc into the brain parenchyma occurs via the blood-brain and blood-cerebrospinal fluid barriers [137]. Its binding with L-histidine, in both plasma and the cerebrospinal fluid, is involved in transferring zinc to target sites, regulating its uptake across the brain barrier systems [137]. Following its uptake, zinc can be transferred freely through the cerebrospinal and the brain extracellular fluid compartments [137]. Zinc homeostasis in the brain is tightly regulated, primarily via three families of proteins: the metallothioneins, which are involved in the regulation and maintenance of intracellular zinc homeostasis [138]; the zinc- and iron-like regulatory proteins, which are responsible for zinc uptake from extracellular fluids into both neurons and glia [139], and the zinc transporters, which are associated with cellular zinc efflux [140]. Interestingly, many of these zinc regulatory proteins also regulate other metal ions. In the brain, zinc is also present in its free ionic form ( $Zn^{2+}$ ) and enriched within synaptic vesicles at glutamatergic nerve terminals from where it is synaptically released during neuronal activity [141–143]. Zinc released in the synaptic cleft affects the expression and activity of N-methyl-D-aspartate (NMDA) and  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) glutamatergic receptors, and glycine ionotropic and  $\gamma$ -aminobutyric acid ( $GABA_A$ ) receptors [144]. Therefore, zinc is intimately linked to the balance of excitation and inhibition signaling in the brain and is essential for memory function and behavior [145].

Zinc homeostasis is impacted in a wide-range of neurological diseases [146, 147]. Although zinc lacks redox activity, it has been demonstrated that excess zinc in the extracellular fluid promotes neurotoxicity and affects protein aggregation [148–150]. Interest in the role of zinc in AD began with the observation that it can precipitate  $A\beta$  into plaques above a concentration of 300 nM [151]. Interestingly, the extracellular concentration of zinc during synaptic transmission rises to 300  $\mu$ M, and it is therefore possible that synaptic transmission contributes to  $A\beta$  deposition in the diseased brain [152–154].  $A\beta$  itself is a metalloprotein that contains binding sites for zinc, which is enriched in plaques and in the cerebral amyloid angiopathy surrounding diseased blood vessels [155–157]. Studies using Tg2576 transgenic mice crossed with zinc transporter 3 knockout mice, which is the transporter responsible for the accumulation of  $Zn^{2+}$  in presynaptic vesicles, have reported reduced plaque load, indicating that synaptic zinc does indeed contribute to  $A\beta$  deposition [158]. Moreover, zinc has a high affinity for  $A\beta$ , and when trapped by accumulated  $A\beta$ , it inhibits APP ferroxidase activity, thereby increasing the levels of iron and ROS [43, 159].

Interestingly, induced attenuation of long-term potentiation (LTP) in dentate granule cells by  $A\beta$  and zinc treatment can be rescued *in vivo* by the administration of calcium-ethylenediaminetetraacetic acid, an extracellular zinc chelator, and by cadmium, a metal that displaces zinc from  $A\beta$  binding [160]. Accordingly, the administration of zinc chelators or zinc ionophores to AD mouse models can restore the physiological metal ions trapped within extracellular  $A\beta$  aggregates, inducing biochemical and anatomical changes which lead to improved cognition [161, 121, 162]. Although there is compelling evidence that zinc/

copper chelators reduce A $\beta$  accumulation, it has recently been demonstrated that this strategy can result in potentially detrimental effects in the healthy brain [121–126]. Depletion of zinc levels in the brain of young mice (2.5 months old) using the zinc/copper chelator clioquinol impaired short- and long-term memory performance. Mechanistically, treatment with clioquinol reduced levels of brain derived neurotrophic factor (BDNF), synaptic plasticity-related proteins and dendritic spine density *in vivo* [163]. These changes were regionally restricted to the hippocampus, cortex, and striatum, without having any effects on the cerebellum, an area devoid of pools of chelatable zinc [163, 164]. These results support the notion that zinc is an important modulator of synaptic plasticity, neurotransmission, neuronal function and cognitive processes in the brain, and highlights the potential detrimental consequences of reducing the availability of zinc in the brains of healthy individuals or in the early stages of AD. Notably, some studies that raised zinc levels via supplementation showed an increase in plaque number and size in mouse models of AD [165–167]. In Tg2576 mice, the intake of zinc acetate caused a reduction of insoluble A $\beta$  in the brain, despite the absence of any significant changes in cognition and behavior [168]. The discrepancies related to the effect of zinc intake on plaque load might be due to its diverse roles in the regulation of A $\beta$ , as zinc has been shown to prevent the proteolytic degradation of A $\beta$  by matrix metalloproteinase 2, and to modulate the activity of the  $\alpha$ -,  $\gamma$ - and  $\beta$ -secretases [169, 170]. Contradictory results are also present when comparing post-mortem analyses of zinc levels in AD brains, as there are studies showing increased, decreased or unchanged zinc levels [171–173, 94, 174, 175].

Zinc not only affects A $\beta$  aggregation, but also the level of hyperphosphorylated tau and the formation of NFTs. Like the effects of zinc on A $\beta$ , low micromolar zinc concentrations can cause the aggregation of tau [176–178]. Zinc is also able to promote tau hyperphosphorylation indirectly via the inactivation of major tau phosphatases, such as protein phosphatase 2A (PP2A) [179, 180]. Importantly, zinc chelators or blockade of synaptic zinc signaling can abolish zinc-mediated tau hyperphosphorylation [181]. Accordingly, zinc supplementation in a tau mouse model intensified the cognitive deficit, in association with an increase in tau phosphorylation, and the number of NFTs in the hippocampus, and a decrease in free zinc ion levels [182]. The influence of zinc on tau pathology was further confirmed when mice with advanced pathology were treated with a copper/zinc chaperone. This caused increased PP2A activity, and was sufficient to improve memory, to decrease tau pathology and to prevent neurodegeneration [183]. This highlights the potential value of targeting zinc in pathological conditions in which tau pathology is present. However, additional investigation regarding the impact of zinc on the activity of tau-related kinases would be welcomed to further validate the protective role of this metal on tau pathology. Oxidative stress is another factor that contributes to the progression of AD, and ROS or exogenous oxidants can promote harmful zinc release from metallothioneins [184–186]. Zinc accumulation can, in turn, induce mitochondrial dysfunction and further oxidative stress, being particularly high in AD neurons expressing mutant APP, PSEN1 and tau [187, 188].

In terms of immunity, zinc seems to be essential for immune cell proliferation, antioxidant response, acquired and innate responses [189, 190]. Interestingly, the molecular mechanisms by which zinc improves immune function are unknown. Studies in mice have shown that dietary zinc is an important nutritional factor for a proper immune response [191, 192].

Accordingly, low zinc status is associated with increased susceptibility to infection and accumulated disease progression by affecting signaling in immune cells, such as microglia [193, 194]. Some of the changes that occur in the brain during aging have been ascribed to altered zinc homeostasis, as only 40% of elderly people have a sufficient zinc intake [147, 195]. Impaired zinc homeostasis promotes immune dysfunction and has been associated with enhanced chronic inflammation dependent on the pathophysiological changes that occur with aging, rather than nutritional intake [196]. Thus, zinc has been suggested as a potential candidate to reverse age-associated changes leading to healthy aging through the reduction of inflammation [197]. Although there is evidence that zinc supplementation in aging improves immune function and leads to decreased mortality from infections, zinc imbalance can result not only from insufficient dietary intake, but also from the impaired activity of zinc transport proteins and zinc-dependent regulation of metabolic pathways [198]. Thus, appropriate zinc supplementation in the aging or diseased brain may help in the prevention as well as treatment of degenerative age-related disease [199, 200].

The above findings, even though at times inconsistent, strongly support the hypothesis that disturbed zinc homeostasis plays an important role in the pathogenesis of AD. Given that zinc contributes to the aggregation of A $\beta$  into plaques as well as the formation of NFTs, inflammation and oxidative stress, research has focused on the development of compounds to neutralize its toxicity in AD. Administration of a metal-protein attenuating compound that affects copper- and zinc-mediated toxic A $\beta$  oligomerization lowered the cerebrospinal fluid levels of A $\beta$  and improved cognition in AD patients [201–203]. Other studies in mouse models of AD have reported comparable results. Supplementation with L-carnosine, a compound with chelating properties, in 3xTg-AD mice reduced the intraneuronal accumulation of A $\beta$ , and completely rescued the mitochondrial dysfunction [204]. Zinc supplementation in the same mouse model delayed hippocampal-dependent memory deficits and strongly reduced both A $\beta$  and tau pathology [205]. The results of these studies highlight the integral role of zinc in the pathogenesis of AD and support the hypothesis that restoring zinc homeostasis is a potential strategy to treat AD. However, it is also important to emphasize the need for mechanistic studies demonstrating how zinc promotes its effects, particularly at cellular and molecular levels in the brain.

### **Manganese (Mn)**

Manganese is a naturally occurring trace element that is essential for human development and brain function. Excessive manganese is neurotoxic and has been linked to developmental disorders and neurodegenerative disorders associated with basal ganglia dysfunction, such as Parkinson's disease and Huntington's disease [206–208]. Moreover, the relevance of manganese for the regulation of brain functions has been further emphasized by the discovery of loss-of-function mutations in genes related to its transport, which lead to neurotoxicity [209]. The neurotoxicity induced by manganese overexposure includes the disruption of mitochondrial function, disruption of neurotransmitter metabolism, alteration of iron homeostasis and induction of oxidative stress [210–214]. Manganese has also been linked to the regulation of brain immunity, and it can have profound effects on microglia and astrocytes, regulating the activation of proinflammatory responses which contribute to its neurotoxic effects [215–217]. The link between manganese and AD, however, is still very

limited. It has been demonstrated that the concentration of manganese does not change in response to human aging and AD [218]. In the periphery, conflicting data have been presented, although a systematic review and meta-analysis has indicated that the manganese level in the serum of AD subjects is reduced compared to that in healthy controls [219]. Although manganese can bind to A $\beta$ , it does so with a weak binding affinity in the millimolar to micromolar range, suggesting that it does not have a large effect on plaque formation [220]. However, studies in non-human primates have shown that chronic manganese exposure produces a cellular stress response that leads to neurodegenerative changes, diffuse A $\beta$  plaques in the frontal cortex, and impairments in visuospatial associative learning [221, 222]. Mechanistically, manganese neurotoxicity seems to be related to excessive iron accumulation via translational repression of APP ferritin [223]. Manganese has also been shown to reduce the glial glutamate transporter-1 (GLT1), which may cause sustained glutamate neurotransmission and excitotoxicity [224]. Likewise, manganese induces activation of inflammation and dysfunction in autophagy, resulting in hippocampal-dependent impairment of learning and memory in mice [217]. In fact, recent bioinformatics analysis has shown that manganese exposure induces the differential expression of genes related to cytokine-cytokine receptor interaction, apoptosis, oxidative phosphorylation, the TLR signaling pathway, and the insulin signaling pathway in neurocytes [225]. Taken together, these studies suggest that changes in manganese homeostasis might contribute to AD via changes in inflammation and oxidative stress. However, further validation is needed, particularly regarding potential disease-modifying effects on A $\beta$  and tau.

## The non-essential metals

### Lead (Pb)

Plumbum (Pb), also known as lead, is a chemical element categorized in the carbon group and considered a heavy metal. Although lead toxicity has been known for many centuries, it was only in 1892 that it was recognized as a serious threat to health following the report that white lead paint on the porches and rails in houses in Brisbane, Australia was the cause of severe neurological disorders in children [226]. Environmental lead absorbed into the bloodstream has a half-life of 30 days. Lead binds to circulating erythrocytes and is distributed throughout the body, eventually accumulating in bone. The half-life of bone-deposited lead can span 20–30 years. Blood lead levels tend to increase during pregnancy, menopause, lactation and aging due to an increase bone demineralization, which causes the release of stored lead [227–229]. The presence of lead in the blood interferes with many organs and functions of the body, but the CNS is by far the most vulnerable. In the brain, the effect of lead can be classified as either morphological or pharmacological. Morphological effects alter neuronal differentiation, myelination, and synaptogenesis [230–232]. Pharmacologically, lead competes with biometals, particularly calcium and to a lesser extent zinc, for their binding sites, thereby disrupting the corresponding essential biometal-dependent mechanisms [233]. Due to its ability to substitute for calcium ions, lead rapidly crosses the blood-brain barrier and causes severe damage to the brain [234]. Lead also interferes with neurotransmitter release, disrupting the function of the GABAergic, dopaminergic and cholinergic systems as well as inhibiting NMDA receptors [235, 236]. Furthermore, lead is involved in the inactivation of glutathione, an important antioxidant

found in cells, by binding to sulfhydryl groups [237]. It is now well known that lead exposure during childhood is associated with cognitive deficits and behavioral disturbances [238, 239]. It has been reported that juvenile lead exposure inhibits NMDA and AMPA receptors, impairing LTP and promoting detrimental synaptic morphological changes in hippocampal CA1 pyramidal neurons, thereby leading to a decline in learning and memory [240]. Similarly, animals exposed to lead either prenatally or postnatally develop memory impairment and cognitive decline later in life [241, 242]. Recently, it has been reported that low-level gestational lead exposure results in dendritic spine alterations in the hippocampus by down-regulating neuroligin-1 protein levels, which in turn results in learning and memory impairment [243]. Given that the effects of early life exposure to lead can persist in adulthood, it is possible that this contributes to the development of AD. In fact, a longitudinal study in former organolead manufacturing workers has shown that past lead exposure is associated with a longitudinal decline in cognitive function and persistent brain lesions [244, 245].

Numerous studies have reported that either developmental or acute lead exposure contributes to the hallmarks of AD, including A $\beta$  accumulation, tau pathology and inflammation. Early lead exposure in young rats increased the expression of APP and  $\beta$ -secretase 1 (BACE1) which subsequently induced AD-like pathology by inducing A $\beta$  accumulation and plaque formation in the hippocampus and cortex [246]. Another study also reported that the expression of APP and BACE1 were increased in the aging rat brain in response to lead exposure during the fetal stage [247]. Likewise, lead exposure during infancy increased the expression of APP, BACE1, transcription factor specific protein 1 (Sp1) and promoted A $\beta$  deposition in aged monkeys [248]. Synergistic exposure to lead, arsenic and cadmium further enhanced APP and BACE1 expression, followed by maximum induction of A $\beta$  production [249]. Developmental lead exposure has also been shown to activate the sterol regulatory element binding protein 2 (SREBP2)-BACE1 pathway, disturbing cholesterol metabolism in the young brain [246]. It is known that cholesterol dyshomeostasis in the brain is closely associated with the etiology of AD and A $\beta$  production [250]. Moreover, acute lead exposure has been shown to increase the accumulation of A $\beta$  in the brain tissue and cerebrospinal fluid through disruption of LRP-1-mediated clearance [251]. Notably, lead exposure also results in an increased level of total and hyperphosphorylated tau. It has been demonstrated that lead exposure increases the protein levels of tau and phosphorylated tau in SH-SY5Y neuroblastoma cells [252]. Similarly, developmental exposure to lead early in life up-regulates tau protein and mRNA, increases serine/threonine phosphatase activity, and CDK5 levels, which together contribute to the formation of NFTs late in life [241, 253]. It has recently been reported that lead also activates GSK-3 $\beta$ - and caspase-3-mediated tauopathy [254].

Lead poisoning is also accompanied by inflammatory events that lead to neuronal death. Individuals exposed to lead present with higher serum TNF- $\alpha$  and granulocyte-colony stimulating factor levels than non-exposed people [255]. Administration of lead to a rat model results in chronic glial activation, together with inflammatory and neurodegenerative features [256]. Likewise, it has been demonstrated that lead exposure results in the activation of microglia and the overproduction of proinflammatory proteins such as inducible nitric oxide synthase (iNOS), IL-1 $\beta$  and TNF- $\alpha$  [257]. These factors are known to contribute to the

brain neurotoxicity in AD [3]. Increased microglial activation due to lead exposure is also accompanied by impaired LTP [257]. The mechanism of lead-induced microglial activation involves activation of the transcriptional factor NF- $\kappa$ B and upregulation of cyclooxygenase-2. Other microglial pathways associated with lead exposure include ERK and protein kinase B (AKT) signaling [258]. In another study, lead exposure was reported to induce abnormal microgliosis by triggering TLR4-MyD88-NF- $\kappa$ B signaling, which directly impacts hippocampal neurogenesis and plasticity [259]. Activation of TLR by lead results in the increased synthesis of proinflammatory cytokines, and the production of reactive nitrogen species and ROS [260]. Collectively, these data provide unambiguous evidence that lead exposure has a long-acting effect and can increase the risk of AD. Unfortunately, no treatment is effective in preventing the effects of lead poisoning and exposure should be therefore avoided.

### Aluminum (Al)

Aluminum is not essential for life but is a well-established neurotoxin. Exposure to high aluminum content in drinking water causes lifelong cerebral impairments, such as loss of concentration and short-term memory deficits [261]. Mass spectrometry studies have demonstrated that aluminum crosses the blood-brain barrier and accumulates in a semipermanent manner [262, 263]. Although no biological process is dependent on aluminum, it can influence more than 200 biologically-relevant reactions and cause various adverse effects on the mammalian brain. These include essential brain processes such as axonal transport, neurotransmitter synthesis, synaptic transmission, phosphorylation or dephosphorylation of proteins, protein degradation, gene expression, and inflammatory responses [264]. Aluminum exhibits one oxidation state, Al<sup>3+</sup>, which has affinity for negatively charged oxygen-donor ligands. Some of the ligands which form strong bonds with aluminum are inorganic and organic phosphates, carboxylate, and deprotonated hydroxyl groups, thereby making DNA, RNA and ATP perfect targets, affecting gene expression, energy metabolism and the action of several kinases and phosphatases [265–267]. Aluminum can also cause the oligomerization of proteins, inducing conformational changes that can inhibit their degradation by proteases, and thus affect their turnover. For instance, strong binding of aluminum to phosphorylated amino acids promotes the self-aggregation and accumulation of highly phosphorylated cytoskeleton proteins, such as neurofilament and microtubule-associated proteins [268]. These properties make the presence of aluminum in the brain toxic, causing the apoptotic death of neurons and glial cells. Aluminum affects LTP, the function of enzymes, including those involved in neurotransmitter synthesis [269, 270]. It also affects voltage-gated calcium channels and neurotransmitter receptors, impairing synaptic transmission [271]. The presence of aluminum therefore leads to a signaling imbalance that disturbs brain function.

More strikingly, exposure to aluminum is also suspected of being linked to neurodegeneration [272]. Several studies reported a higher incidence of AD or AD mortality in areas with high levels of aluminum in the drinking water, suggesting a strong association between aluminum and AD [273–277]. This was confirmed by later studies which demonstrated the ability of aluminum to induce neurofibrillary degeneration and promote the appearance of tangle-like structures that resembled the NFTs found in the brains of AD

patients [278–281]. Moreover, aluminum accumulation was described in NFT-bearing neurons of AD brains [282–284]. When the effects of oral aluminum administration were studied using a tau mouse model showing slow progressive tau accumulation, higher tau aggregation, apoptosis and neurological dysfunction were observed in animals that already had a pathological process causing tau aggregation, but not in the controls [285], thereby suggesting an exacerbating effect of aluminum on tau pathology. Aluminum achieves these effects by enhancing the activity of the tau kinases CDK5 and GSK-3 $\beta$ , inhibiting the dephosphorylation of tau, and enhancing its aggregation [286–290]. Interestingly, aluminum is preferentially taken up by glial cells, which induces the production of inflammatory cytokines, including IL-6 [291, 52, 292]. IL-6 in turn has been reported to induce phosphorylation of tau by dysregulating the CDK5/p35 cascade [293, 294]. Increased glial activation and an inflammatory response have been described upon aluminum treatment in rats [295]; however, whether glial activation due to aluminum exposure plays a role in the acceleration of an early process in the formation of AD pathology needs to be studied further.

Although the effects of aluminum on AD pathology were first attributed to its interaction with tau, it was later demonstrated that it also affects A $\beta$  by promoting its production, aggregation, and by inhibiting its degradation [296–299]. Oral administration of aluminum to AD mice induced an increase in the amount of A $\beta$ , both in its secreted and accumulated forms, and increased deposition in plaques [300]. In addition, A $\beta$  coupled with aluminum is more toxic than A $\beta$  itself as it causes membrane disruption and perturbation of neural calcium homeostasis and mitochondrial respiration [301–303]. Aluminum can also influence the expression of iron-binding proteins expression with IRE/IRP sequences in their mRNA, causing an increase in iron concentration [41, 304, 305]. The presence of aluminum in the brain can therefore modulate the expression, distribution and accumulation of APP and induce the dysregulation of iron-modulated signaling pathways, by interacting with IRE mRNA regions [306, 307]. Consequently, aluminum stimulates iron-induced membrane lipid peroxidation and causes oxidative damage [308–310]. Despite its non-redox status, several studies have suggested that aluminum has strong oxidative activity [311, 312]. The interaction of aluminum with iron generates labile iron from iron-containing enzymes and proteins, thereby increasing the intracellular pool of free iron, which in turn leads to the formation of ROS [313]. Aluminum also decreases the activity of some antioxidant enzymes such as catalase, superoxide dismutase, and glutathione peroxidase, thus exacerbating the neuronal damage induced by oxidative stress in neurodegenerative disease such as AD [314, 315].

Aluminum has also been reported to affect neurotransmission. Due to its ability to block A $\beta$ -mediated formation of calcium permeable ion channel, aluminum can inhibit the increase in calcium levels induced by neurotrophic factors such as BDNF [316–318]. The level of other neurotransmitters, such as serotonin, dopamine, glutamate and aspartate, have also been reported to decrease upon aluminum exposure [319, 320]. A lower availability of glutamate induced by aluminum has been attributed to the induction of glutamine synthetase and inhibition of glutaminase activity in astrocytes [292]. Moreover, it has been reported that aluminum affects the cholinergic system, which has been shown to degenerate in AD pathogenesis [321, 322]. Thus, like the therapeutic approaches used to block the neurotoxic effects of other metals, aluminum chelation has been studied as a potential therapy for AD



[323]. The use of deferoxamine, a chelator of aluminum and iron, as well as silicates, which couples with aluminum and reduces its toxicity, has been shown to attenuate cognitive decline in AD patients [324, 325]. Despite not being preventative, aluminum chelators could potentially minimize the neurodegenerative effects of aluminum in patients with known exposure throughout their lives.

### Cadmium (Cd)

Cadmium is a carcinogenic heavy metal that is present in the environment. Unlike many heavy metals, due to its water-soluble property, cadmium can be transported from soil to plants and concentrated in the food chain [326]. Although the effect of cadmium on the plant can be detrimental, some plants, such as tobacco, show cadmium tolerance [327, 328]. Therefore, consumption of tobacco products or inhalation of tobacco smoke increases the risk of cadmium-related morbidities in the general population [329]. Once taken into the body, cadmium accumulates in the kidney and liver and has an extremely long half-life of 20–40 years [330–332]. Chronic cadmium exposure is associated with hypertension, kidney dysfunction, bone demineralization, and neurological diseases [333–337]. Cadmium is known to cross the blood-brain barrier and eventually accumulate in the brain, leading to neurotoxicity [338]. In the brain, cadmium induces activation of various signaling pathways involved in inflammation, oxidative stress, and neuronal apoptosis [339, 340, 337].

Recent epidemiological studies reported that blood cadmium levels were significantly associated with AD-related mortality among older adults [341, 342]. In the AD brain, there is increasing evidence that cadmium is involved in the aggregation of A $\beta$  plaques [343–345]. In an *in vivo* study, APP/PS1 mice administered cadmium in their drinking water exhibited an increase in the number and size of plaques [343]. Cadmium ions can interact with the A $\beta$ , subsequently promoting formation of plaques [344]. Furthermore, it has been hypothesized that cadmium treatment downregulates the expression of  $\alpha$ -secretase (ADAM10) and neutral endopeptidase which play essential roles in reducing A $\beta$  levels in the brain [346, 343]. Interestingly, a recent study has reported that the synergistic effect of cadmium, lead, and arsenic further enhance amyloidogenic processing by increasing APP, BACE1 and PSEN1 expression, suggesting an interactive effect of cadmium with other metals in AD [249]. In addition to its effects on A $\beta$ , cadmium is also involved in the conformation and self-aggregation of tau in the AD brain [347, 348]. Cadmium has been reported to bind to the third repeat (R3) of the microtubule-binding domain of tau. As a result, the R3 domain partially loses its random coil conformation and gains an  $\alpha$ -helix structure which promotes the self-aggregation of tau. Moreover, cadmium treatment selectively blocks muscarinic M<sub>1</sub> receptors which are known to regulate GSK-3 $\beta$  negatively and subsequently increase both total and phosphorylated tau protein [349, 347, 350]. These data support the notion that cadmium is one factor that could be involved in the development of AD.

With regards to immunity, human astrocytes treated with a non-toxic concentration of cadmium have been shown to release an elevated level of IL-6 and IL-8 via activation of the mitogen-activated protein kinase (MAPK) and NF- $\kappa$ B signaling pathways, possibly leading to neuroinflammation and neuronal death [351]. Notably, it has been reported that increased IL-6 and IL-8 expression are associated with AD pathogenesis [352]. Moreover, cadmium has

been shown to induce astrocyte cytotoxicity by increasing intracellular calcium ions via the MAPK and PI3K/AKT signaling pathways [353]. These data suggest that the regulation of cadmium-induced  $\text{Ca}^{2+}$  homeostasis may be a good strategy for the prevention of related diseases in the CNS. However, there is still a lack of *in vivo* studies showing the effect of cadmium on neuroinflammation in AD mouse models.

## Concluding remarks

Altogether, evidence strongly supports that disruption in the homeostasis of essential metals and the accumulation of non-essential metals disturb the cellular metabolism, antioxidant defense, and immune responses, leading to the onset and progression of AD. Not surprisingly, greater emphasis has been given to the interaction of metals and  $\text{A}\beta$ , in which it has been shown that biometals interfere with APP function and facilitate aggregation of  $\text{A}\beta$  into plaques. The relationship between biometals and tau, however, has only recently emerged, and these studies have shown that changes in the metabolism of metals are detrimental to tau function, resulting in its loss-of-function and aggregation; however, the mechanism of how biometals affect tau function remains elusive. Likewise, most findings regarding to the interaction between brain immunity and biometals have been limited to evidence of the overproduction of inflammatory mediators (*i.e.*, cytokines) in response to changes in metal metabolism, with a clear cellular and molecular mechanism still to be established. Nevertheless, studies using metal chelators have shown promising disease-modifying properties *in vitro* and in AD mouse models, emphasizing the potential therapeutic value of this approach, as well as the important role of metals in AD.

In moving forward in the understanding of the complex links among biometals, AD, and immunity, studies will need to provide greater mechanistic evidence at cellular and molecular levels for how essential and non-essential metals affect the brain, with respect to the chronic accumulation of  $\text{A}\beta$ , tau, and immune mediators. In this context, genetic approaches, like CRISPR gene editing, targeting specific molecular components of essential metals metabolism (*e.g.*, point mutations in binding sites, enzymes deletion) in cell culture models are likely to provide better defined data on how biometals regulate cell function and signaling, before moving to more complex *in vivo* models. At cellular level, there is great need for research on how biometals modulate the functions and interactions of microglia and astrocytes during homeostasis and disease states, particularly regarding their roles in immune surveillance and response, and synaptic pruning. Such studies will demonstrate whether the imbalance of biometals affect the capacity of glial cells to build an immune response to properly recognize and clear pathological forms of  $\text{A}\beta$  and tau. Moreover, it is also not clear whether the potential loss-of-function of glial cells caused by changes in the metabolism of biometals disrupts neuronal function due to inappropriate pruning of neuritic spines and/or other mechanisms, which can have an impact in the cognitive decline in AD. Finally, considering that proteins generally display binding sites to multiple metals, it will be important to determine how distinct biometals interact during physiological and pathological conditions to modulate cellular responses in the brain.

## Acknowledgements

We appreciate the editing support from Ms. Rowan Tweedale. This work was funded by the Australian National Health and Medical Research Council [GNT1128436, GNT1129192, GNT1139469 (RM)] and the National Institutes of Health [R01ES024331 (MK)].

## Abbreviations used

<b>A<math>\beta</math></b>	$\beta$ -amyloid
<b>AD</b>	Alzheimer's disease
<b>AMPA</b>	$\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole propionate
<b>APOE</b>	apolipoprotein E
<b>APP</b>	amyloid precursor protein
<b>BACE1</b>	$\beta$ -secretase-1
<b>BDNF</b>	brain-derived neurotrophic factor
<b>CD</b>	cluster of differentiation
<b>CDK5</b>	cyclin-dependent kinase 5
<b>CNS</b>	central nervous system
<b>DMT1</b>	divalent metal transporter 1
<b>DNA</b>	deoxyribonucleic acid
<b>ERK</b>	extracellular signal-regulated kinase
<b>FPN1</b>	ferroportin 1
<b>GABA</b>	gamma-aminobutyric acid
<b>GSK-3<math>\beta</math></b>	glycogen synthase kinase-3 $\beta$
<b>IL</b>	interleukini
<b>iNOS</b>	inducible nitric oxide synthase
<b>IRE</b>	iron-responsive elements
<b>IRP</b>	iron-regulatory proteins
<b>LPS</b>	lipopolysaccharide
<b>LRP-1</b>	lipoprotein receptor-related protein-1
<b>LTP</b>	long-term potentiation
<b>MAPK</b>	mitogen-activated protein kinase
<b>mRNA</b>	messenger RNA

<b>MyD88</b>	myeloid differentiation primary response 88
<b>NF-<math>\kappa</math>B</b>	nuclear factor- $\kappa$ B
<b>NFTs</b>	neurofibrillary tangles
<b>NMDA</b>	N-methyl-D-aspartate
<b>PI3K</b>	phosphatidylinositol-4,5-bisphosphate 3-kinase
<b>PP2A</b>	protein phosphatase 2A
<b>PSEN1</b>	presenilin-1
<b>PSEN2</b>	presenilin-2
<b>ROS</b>	reactive oxygen species
<b>SREBP2</b>	sterol regulatory element binding protein 2
<b>TGN</b>	trans-Golgi network
<b>TLR</b>	toll-like receptor
<b>TNF-<math>\alpha</math></b>	tumor necrosis factor- $\alpha$
<b>TREM2</b>	triggering receptor expressed on myeloid cells 2

## References

- [1]. United Nations, Department of Economic and Social Affairs, Population Division (2017). World Population Prospects: The 2017 Revision, Key Findings and Advance Tables.
- [2]. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbaek G, Teri L & Mukadam N (2017). Dementia prevention, intervention, and care. *Lancet*. 390,2673–734. [PubMed: 28735855]
- [3]. Newcombe EA, Camats-Perna J, Silva ML, Valmas N, Huat TJ & Medeiros R (2018). Inflammation: The link between comorbidities, genetics, and alzheimer's disease. *J Neuroinflammation*. 15,276. [PubMed: 30249283]
- [4]. Plummer S, Van Den Heuvel C, Thornton E, Corrigan F & Cappai R (2016). The neuroprotective properties of the amyloid precursor protein following traumatic brain injury. *Aging Dis*. 7,163–79. [PubMed: 27114849]
- [5]. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, Mcdade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S & Morris JC (2012). Clinical and biomarker changes in dominantly inherited alzheimer's disease. *N Engl J Med*. 367,795–804. [PubMed: 22784036]
- [6]. Lee MS & Tsai LH (2003). Cdk5: One of the links between senile plaques and neurofibrillary tangles? *J Alzheimers Dis*. 5,127–37. [PubMed: 12719630]
- [7]. Zheng WH, Bastianetto S, Mennicken F, Ma W & Kar S (2002). Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. *Neuroscience*. 115,201–11. [PubMed: 12401334]

- [8]. Cowan CM, Bossing T, Page A, Shepherd D & Mudher A (2010). Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. *Acta Neuropathol.* 120,593–604. [PubMed: 20617325]
- [9]. Jeganathan S, Hascher A, Chinnathambi S, Biernat J, Mandelkow EM & Mandelkow E (2008). Proline-directed pseudo-phosphorylation at at8 and phf1 epitopes induces a compaction of the paperclip folding of tau and generates a pathological (mc-1) conformation. *J Biol Chem.* 283,32066–76. [PubMed: 18725412]
- [10]. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM & Trojanowski JQ (2005). Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. *Proc Natl Acad Sci U S A.* 102,227–31. [PubMed: 15615853]
- [11]. Arriagada PV, Growdon JH, Hedley-Whyte ET & Hyman BT (1992). Neurofibrillary tangles but not senile plaques parallel duration and severity of alzheimer's disease. *Neurology.* 42,631–9. [PubMed: 1549228]
- [12]. Ballatore C, Lee VM & Trojanowski JQ (2007). Tau-mediated neurodegeneration in alzheimer's disease and related disorders. *Nat Rev Neurosci.* 8,663–72. [PubMed: 17684513]
- [13]. Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rube CE, Walter J, Heneka MT, Hartmann T, Menger MD & Fassbender K (2012). Tlr2 is a primary receptor for alzheimer's amyloid beta peptide to trigger neuroinflammatory activation. *J Immunol.* 188,1098–107. [PubMed: 22198949]
- [14]. Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Pina-Crespo JC, Zhang M, Zhang N, Chen X, Bu G, An Z, Huang TY & Xu H (2018). Trem2 is a receptor for beta-amyloid that mediates microglial function. *Neuron.* 97,1023–31.e7. [PubMed: 29518356]
- [15]. Hellstrom-Lindahl E, Ravid R & Nordberg A (2008). Age-dependent decline of neprilysin in alzheimer's disease and normal brain: Inverse correlation with a beta levels. *Neurobiol Aging.* 29,210–21. [PubMed: 17098332]
- [16]. Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B & Pasinetti GM (2007). Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop alzheimer's disease. *Neurobiol Aging.* 28,824–30. [PubMed: 16769157]
- [17]. Kitazawa M, Oddo S, Yamasaki TR, Green KN & Laferla FM (2005). Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of alzheimer's disease. *J Neurosci.* 25,8843–53. [PubMed: 16192374]
- [18]. Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE & Laferla FM (2011). Inflammation induced by infection potentiates tau pathological features in transgenic mice. *Am J Pathol.* 178,2811–22. [PubMed: 21531375]
- [19]. Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O, Kugler S & Ikezu T (2015). Depletion of microglia and inhibition of exosome synthesis halt tau propagation. *Nat Neurosci.* 18,1584–93. [PubMed: 26436904]
- [20]. Hickman SE, Allison EK & El Khoury J (2008). Microglial dysfunction and defective beta-amyloid clearance pathways in aging alzheimer's disease mice. *J Neurosci.* 28,8354–60. [PubMed: 18701698]
- [21]. Njie EG, Boelen E, Stassen FR, Steinbusch HW, Borchelt DR & Streit WJ (2012). Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. *Neurobiol Aging.* 33,195.e1–12.
- [22]. Castillo E, Leon J, Mazzei G, Abolhassani N, Haruyama N, Saito T, Saido T, Hokama M, Iwaki T, Ohara T, Ninomiya T, Kiyohara Y, Sakumi K, Laferla FM & Nakabeppu Y (2017). Comparative profiling of cortical gene expression in alzheimer's disease patients and mouse models demonstrates a link between amyloidosis and neuroinflammation. *Sci Rep.* 7,17762. [PubMed: 29259249]
- [23]. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ & Stevens B (2016). Complement and microglia mediate early synapse loss in alzheimer mouse models. *Science.* 352,712–6. [PubMed: 27033548]

- [24]. Programme UNE, Nations U & Publications UN Unep year book 2014: Emerging issues in our global environment: UNITED NATIONS PUBN; 2015.
- [25]. Prüss-Üstün A & Neira M Preventing disease through healthy environments: A global assessment of the burden of disease from environmental risks: World Health Organization; 2016.
- [26]. Que EL, Domaille DW & Chang CJ (2008). Metals in neurobiology: Probing their chemistry and biology with molecular imaging. *Chem Rev.* 108,1517–49. [PubMed: 18426241]
- [27]. Torti SV, Manz DH, Paul BT, Blanchette-Farra N & Torti FM (2018). Iron and cancer. *Annu Rev Nutr.* 38,97–125. [PubMed: 30130469]
- [28]. Hower V, Mendes P, Torti FM, Laubenbacher R, Akman S, Shulaev V & Torti SV (2009). A general map of iron metabolism and tissue-specific subnetworks. *Mol Biosyst.* 5,422–43. [PubMed: 19381358]
- [29]. Liu JL, Fan YG, Yang ZS, Wang ZY & Guo C (2018). Iron and alzheimer's disease: From pathogenesis to therapeutic implications. *Front Neurosci.* 12,632. [PubMed: 30250423]
- [30]. Hentze MW, Muckenthaler MU, Galy B & Camaschella C (2010). Two to tango: Regulation of mammalian iron metabolism. *Cell.* 142,24–38. [PubMed: 20603012]
- [31]. Camaschella C (2015). Iron-deficiency anemia. *N Engl J Med.* 373,485–6.
- [32]. Mesquita SD, Ferreira AC, Sousa JC, Santos NC, Correia-Neves M, Sousa N, Palha JA & Marques F (2012). Modulation of iron metabolism in aging and in alzheimer's disease: Relevance of the choroid plexus. *Front Cell Neurosci.* 6,25. [PubMed: 22661928]
- [33]. Pirpamer L, Hofer E, Gesierich B, De Guio F, Freudenberger P, Seiler S, Duering M, Jouvent E, Duchesnay E, Dichgans M, Ropele S & Schmidt R (2016). Determinants of iron accumulation in the normal aging brain. *Neurobiol Aging.* 43,149–55. [PubMed: 27255824]
- [34]. Xu J, Jia Z, Knutson MD & Leeuwenburgh C (2012). Impaired iron status in aging research. *Int J Mol Sci.* 13,2368–86. [PubMed: 22408459]
- [35]. Smith MA, Zhu X, Tabaton M, Liu G, Mckee DW Jr., Cohen ML, Wang X, Siedlak SL, Dwyer BE, Hayashi T, Nakamura M, Nunomura A & Perry G (2010). Increased iron and free radical generation in preclinical alzheimer disease and mild cognitive impairment. *J Alzheimers Dis.* 19,363–72. [PubMed: 20061651]
- [36]. El Tannir El Tayara N, Delatour B, Le Cudennec C, Guegan M, Volk A & Dhenain M (2006). Age-related evolution of amyloid burden, iron load, and mr relaxation times in a transgenic mouse model of alzheimer's disease. *Neurobiol Dis.* 22,199–208. [PubMed: 16337798]
- [37]. Van Rooden S, Maat-Schieman ML, Nabuurs RJ, Van Der Weerd L, Van Duijn S, Van Duinen SG, Natta R, Van Buchem MA & Van Der Grond J (2009). Cerebral amyloidosis: Postmortem detection with human 7.0-t mr imaging system. *Radiology.* 253,788–96. [PubMed: 19789230]
- [38]. Van Rooden S, Versluis MJ, Liem MK, Milles J, Maier AB, Oleksik AM, Webb AG, Van Buchem MA & Van Der Grond J (2014). Cortical phase changes in alzheimer's disease at 7t mri: A novel imaging marker. *Alzheimers Dement.* 10,e19–26. [PubMed: 23712002]
- [39]. Vanhoutte G, Dewachter I, Borghgraef P, Van Leuven F & Van Der Linden A (2005). Noninvasive in vivo mri detection of neuritic plaques associated with iron in app[v717i] transgenic mice, a model for alzheimer's disease. *Magn Reson Med.* 53,607–13. [PubMed: 15723413]
- [40]. Diouf I, Fazlollahi A, Bush AI & Ayton S (2018). Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying beta-amyloid pathology. *Neurobiol Dis.* 124,335–9. [PubMed: 30557658]
- [41]. Cho HH, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X & Rogers JT (2010). Selective translational control of the alzheimer amyloid precursor protein transcript by iron regulatory protein-1. *J Biol Chem.* 285,31217–32. [PubMed: 20558735]
- [42]. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T & Gullans SR (2002). An iron-responsive element type ii in the 5'-untranslated region of the alzheimer's amyloid precursor protein transcript. *J Biol Chem.* 277,45518–28. [PubMed: 12198135]
- [43]. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikke K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, Mclean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT & Bush AI (2010). Iron-export ferroxidase activity of

- beta-amyloid precursor protein is inhibited by zinc in alzheimer's disease. *Cell*. 142,857–67. [PubMed: 20817278]
- [44]. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA & Smith MA (2000). In situ oxidative catalysis by neurofibrillary tangles and senile plaques in alzheimer's disease: A central role for bound transition metals. *J Neurochem*. 74,270–9. [PubMed: 10617129]
- [45]. Smith MA, Harris PL, Sayre LM & Perry G (1997). Iron accumulation in alzheimer disease is a source of redox-generated free radicals. *Proc Natl Acad Sci U S A*. 94,9866–8. [PubMed: 9275217]
- [46]. Good PF, Perl DP, Bierer LM & Schmeidler J (1992). Selective accumulation of aluminum and iron in the neurofibrillary tangles of alzheimer's disease: A laser microprobe (lamma) study. *Ann Neurol*. 31,286–92. [PubMed: 1637136]
- [47]. Perez M, Valpuesta JM, De Garcini EM, Quintana C, Arrasate M, Lopez Carrascosa JL, Rabano A, Garcia De Yebenes J & Avila J (1998). Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. *Am J Pathol*. 152,1531–9. [PubMed: 9626057]
- [48]. Connor JR, Menzies SL, St Martin SM & Mufson EJ (1992). A histochemical study of iron, transferrin, and ferritin in alzheimer's diseased brains. *J Neurosci Res*. 31,75–83. [PubMed: 1613823]
- [49]. Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K & Joshi JG (1990). Ferritin is a component of the neuritic (senile) plaque in alzheimer dementia. *Acta Neuropathol*. 81,105–10. [PubMed: 2082650]
- [50]. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P & Youdim MB (1990). Brain iron and ferritin in parkinson's and alzheimer's diseases. *J Neural Transm Park Dis Dement Sect*. 2,327–40. [PubMed: 2078310]
- [51]. Van Duijn S, Bulk M, Van Duinen SG, Nabuurs RJA, Van Buchem MA, Van Der Weerd L & Nettekoven R (2017). Cortical iron reflects severity of alzheimer's disease. *J Alzheimers Dis*. 60,1533–45. [PubMed: 29081415]
- [52]. Oshiro S, Kawahara M, Kuroda Y, Zhang C, Cai Y, Kitajima S & Shirao M (2000). Glial cells contribute more to iron and aluminum accumulation but are more resistant to oxidative stress than neuronal cells. *Biochim Biophys Acta*. 1502,405–14. [PubMed: 11068183]
- [53]. Lopes KO, Sparks DL & Streit WJ (2008). Microglial dystrophy in the aged and alzheimer's disease brain is associated with ferritin immunoreactivity. *Glia*. 56,1048–60. [PubMed: 18442088]
- [54]. Kawamata T, Tooyama I, Yamada T, Walker DG & McGeer PL (1993). Lactotransferrin immunocytochemistry in alzheimer and normal human brain. *Am J Pathol*. 142,1574–85. [PubMed: 8494052]
- [55]. Leveugle B, Spik G, Perl DP, Bouras C, Fillit HM & Hof PR (1994). The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: A comparative immunohistochemical analysis. *Brain Res*. 650,20–31. [PubMed: 7953673]
- [56]. Jefferies WA, Food MR, Gabathuler R, Rothenberger S, Yamada T, Yasuhara O & McGeer PL (1996). Reactive microglia specifically associated with amyloid plaques in alzheimer's disease brain tissue express melanotransferrin. *Brain Res*. 712,122–6. [PubMed: 8705294]
- [57]. Smith MA, Wehr K, Harris PL, Siedlak SL, Connor JR & Perry G (1998). Abnormal localization of iron regulatory protein in alzheimer's disease. *Brain Res*. 788,232–6. [PubMed: 9555030]
- [58]. Wang P, Wu Q, Wu W, Li H, Guo Y, Yu P, Gao G, Shi Z, Zhao B & Chang YZ (2017). Mitochondrial ferritin deletion exacerbates beta-amyloid-induced neurotoxicity in mice. *Oxid Med Cell Longev*. 2017,1020357. [PubMed: 28191272]
- [59]. Boopathi S & Kolandaivel P (2016). Fe(2+) binding on amyloid beta-peptide promotes aggregation. *Proteins*. 84,1257–74. [PubMed: 27214008]
- [60]. Garzon-Rodriguez W, Yatsimirsky AK & Glabe CG (1999). Binding of zn(ii), cu(ii), and fe(ii) ions to alzheimer's a beta peptide studied by fluorescence. *Bioorg Med Chem Lett*. 9,2243–8. [PubMed: 10465554]
- [61]. Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE & Bush AI (2004). Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of alzheimer's a beta peptides. *J Biol Inorg Chem*. 9,954–60. [PubMed: 15578276]

- [62]. Schubert D & Chevion M (1995). The role of iron in beta amyloid toxicity. *Biochem Biophys Res Commun.* 216,702–7. [PubMed: 7488167]
- [63]. Jiang D, Li X, Williams R, Patel S, Men L, Wang Y & Zhou F (2009). Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: Binding affinities, redox properties, and relevance to iron-induced oxidative stress in alzheimer's disease. *Biochemistry.* 48,7939–47. [PubMed: 19601593]
- [64]. Xian-Hui D, Wei-Juan G, Tie-Mei S, Hong-Lin X, Jiang-Tao B, Jing-Yi Z & Xi-Qing C (2015). Age-related changes of brain iron load changes in the frontal cortex in appsw/ps1delta9 transgenic mouse model of alzheimer's disease. *J Trace Elem Med Biol.* 30,118–23. [PubMed: 25575693]
- [65]. Skjorringe T, Burkhart A, Johnsen KB & Moos T (2015). Divalent metal transporter 1 (dmt1) in the brain: Implications for a role in iron transport at the blood-brain barrier, and neuronal and glial pathology. *Front Mol Neurosci.* 8,19. [PubMed: 26106291]
- [66]. Ward DM & Kaplan J (2012). Ferroportin-mediated iron transport: Expression and regulation. *Biochim Biophys Acta.* 1823,1426–33. [PubMed: 22440327]
- [67]. Mita H, Yui Y, Taniguchi N, Yasueda H & Shida T (1985). Increased activity of 5-lipoxygenase in polymorphonuclear leukocytes from asthmatic patients. *Life Sci.* 37,907–14. [PubMed: 2993772]
- [68]. Tian J, Zheng W, Li XL, Cui YH & Wang ZY (2018). Lower expression of ndfp1 is associated with alzheimer disease pathogenesis through decreasing dmt1 degradation and increasing iron influx. *Front Aging Neurosci.* 10,165. [PubMed: 29937728]
- [69]. Zheng W, Xin N, Chi ZH, Zhao BL, Zhang J, Li JY & Wang ZY (2009). Divalent metal transporter 1 is involved in amyloid precursor protein processing and abeta generation. *Faseb j.* 23,4207–17. [PubMed: 19679638]
- [70]. Xie L, Zheng W, Xin N, Xie JW, Wang T & Wang ZY (2012). Ebselen inhibits iron-induced tau phosphorylation by attenuating dmt1 up-regulation and cellular iron uptake. *Neurochem Int.* 61,334–40. [PubMed: 22634399]
- [71]. Becerril-Ortega J, Bordji K, Freret T, Rush T & Buisson A (2014). Iron overload accelerates neuronal amyloid-beta production and cognitive impairment in transgenic mice model of alzheimer's disease. *Neurobiol Aging.* 35,2288–301. [PubMed: 24863668]
- [72]. Peters DG, Pollack AN, Cheng KC, Sun D, Saido T, Haaf MP, Yang QX, Connor JR & Meadowcroft MD (2018). Dietary lipophilic iron alters amyloidogenesis and microglial morphology in alzheimer's disease knock-in app mice. *Metallomics.* 10,426–43. [PubMed: 29424844]
- [73]. Zhang Y & He ML (2017). Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposits in app/ps1 mice. *Brain Res.* 1677,86–92. [PubMed: 28963052]
- [74]. Jiang C, Zou X, Zhu R, Shi Y, Wu Z, Zhao F & Chen L (2018). The correlation between accumulation of amyloid beta with enhanced neuroinflammation and cognitive impairment after intraventricular hemorrhage. *J Neurosurg.* 1–10.
- [75]. Meng FX, Hou JM & Sun TS (2017). In vivo evaluation of microglia activation by intracranial iron overload in central pain after spinal cord injury. *J Orthop Surg Res.* 12,75. [PubMed: 28521818]
- [76]. Zhang X, Surguladze N, Slagle-Webb B, Cozzi A & Connor JR (2006). Cellular iron status influences the functional relationship between microglia and oligodendrocytes. *Glia.* 54,795–804. [PubMed: 16958088]
- [77]. Urrutia P, Aguirre P, Esparza A, Tapia V, Mena NP, Arredondo M, Gonzalez-Billault C & Nunez MT (2013). Inflammation alters the expression of dmt1, fpn1 and hepcidin, and it causes iron accumulation in central nervous system cells. *J Neurochem.* 126,541–9. [PubMed: 23506423]
- [78]. Kroner A, Greenhalgh AD, Zarruk JG, Passos Dos Santos R, Gaestel M & David S (2014). Tnf and increased intracellular iron alter macrophage polarization to a detrimental m1 phenotype in the injured spinal cord. *Neuron.* 83,1098–116. [PubMed: 25132469]
- [79]. Kim BE, Nevitt T & Thiele DJ (2008). Mechanisms for copper acquisition, distribution and regulation. *Nat Chem Biol.* 4,176–85. [PubMed: 18277979]
- [80]. Madsen E & Gitlin JD (2007). Copper and iron disorders of the brain. *Annu Rev Neurosci.* 30,317–37. [PubMed: 17367269]



- [81]. Kaler SG (2011). Atp7a-related copper transport diseases-emerging concepts and future trends. *Nat Rev Neurol.* 7,15–29. [PubMed: 21221114]
- [82]. Gaier ED, Eipper BA & Mains RE (2013). Copper signaling in the mammalian nervous system: Synaptic effects. *J Neurosci Res.* 91,2–19. [PubMed: 23115049]
- [83]. Lutsenko S, Bhattacharjee A & Hubbard AL (2010). Copper handling machinery of the brain. *Metallomics.* 2,596–608. [PubMed: 21072351]
- [84]. Opazo CM, Greenough MA & Bush AI (2014). Copper: From neurotransmission to neuroproteostasis. *Front Aging Neurosci.* 6,143. [PubMed: 25071552]
- [85]. Bandmann O, Weiss KH & Kaler SG (2015). Wilson’s disease and other neurological copper disorders. *Lancet Neurol.* 14,103–13. [PubMed: 25496901]
- [86]. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, Von Bohlen A, Schulz-Schaeffer W, Giese A, Westaway D & Kretzschmar H (1997). The cellular prion protein binds copper in vivo. *Nature.* 390,684–7. [PubMed: 9414160]
- [87]. Rose F, Hodak M & Bernholc J (2011). Mechanism of copper(ii)-induced misfolding of parkinson’s disease protein. *Sci Rep.* 1,11. [PubMed: 22355530]
- [88]. Siggs OM, Cruite JT, Du X, Rutschmann S, Masliah E, Beutler B & Oldstone MB (2012). Disruption of copper homeostasis due to a mutation of atp7a delays the onset of prion disease. *Proc Natl Acad Sci U S A.* 109,13733–8. [PubMed: 22869751]
- [89]. Valentine JS & Hart PJ (2003). Misfolded cuznsod and amyotrophic lateral sclerosis. *Proc Natl Acad Sci U S A.* 100,3617–22. [PubMed: 12655070]
- [90]. Xiao G, Fan Q, Wang X & Zhou B (2013). Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding. *Proc Natl Acad Sci U S A.* 110,14995–5000. [PubMed: 23980182]
- [91]. Squitti R, Ghidoni R, Siotto M, Ventriglia M, Benussi L, Paterlini A, Magri M, Binetti G, Cassetta E, Caprara D, Vernieri F, Rossini PM & Pasqualetti P (2014). Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to alzheimer disease. *Ann Neurol.* 75,574–80. [PubMed: 24623259]
- [92]. Ventriglia M, Bucossi S, Panetta V & Squitti R (2012). Copper in alzheimer’s disease: A meta-analysis of serum, plasma, and cerebrospinal fluid studies. *J Alzheimers Dis.* 30,981–4. [PubMed: 22475798]
- [93]. Wang ZX, Tan L, Wang HF, Ma J, Liu J, Tan MS, Sun JH, Zhu XC, Jiang T & Yu JT (2015). Serum iron, zinc, and copper levels in patients with alzheimer’s disease: A replication study and meta-analyses. *J Alzheimers Dis.* 47,565–81. [PubMed: 26401693]
- [94]. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL & Markesbery WR (1998). Copper, iron and zinc in alzheimer’s disease senile plaques. *J Neurol Sci.* 158,47–52. [PubMed: 9667777]
- [95]. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A & Miklossy J (2006). Synchrotron-based infrared and x-ray imaging shows focalized accumulation of cu and zn co-localized with beta-amyloid deposits in alzheimer’s disease. *J Struct Biol.* 155,30–7. [PubMed: 16325427]
- [96]. Rembach A, Hare DJ, Lind M, Fowler CJ, Cherny RA, Mclean C, Bush AI, Masters CL & Roberts BR (2013). Decreased copper in alzheimer’s disease brain is predominantly in the soluble extractable fraction. *Int J Alzheimers Dis.* 2013,623241. [PubMed: 24228186]
- [97]. James SA, Volitakis I, Adlard PA, Duce JA, Masters CL, Cherny RA & Bush AI (2012). Elevated labile cu is associated with oxidative pathology in alzheimer disease. *Free Radic Biol Med.* 52,298–302. [PubMed: 22080049]
- [98]. Multhaup G, Schlichsupp A, Hesse L, Behr D, Ruppert T, Masters CL & Beyreuther K (1996). The amyloid precursor protein of alzheimer’s disease in the reduction of copper(ii) to copper(i). *Science.* 271,1406–9. [PubMed: 8596911]
- [99]. Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI & Li QX (2002). Overexpression of alzheimer’s disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. *J Biol Chem.* 277,44670–6. [PubMed: 12215434]
- [100]. White AR, Reyes R, Mercer JF, Camakaris J, Zheng H, Bush AI, Multhaup G, Beyreuther K, Masters CL & Cappai R (1999). Copper levels are increased in the cerebral cortex and liver of app and aplp2 knockout mice. *Brain Res.* 842,439–44. [PubMed: 10526140]

- [101]. Acevedo KM, Hung YH, Dalziel AH, Li QX, Laughton K, Wikhe K, Rembach A, Roberts B, Masters CL, Bush AI & Camakaris J (2011). Copper promotes the trafficking of the amyloid precursor protein. *J Biol Chem.* 286,8252–62. [PubMed: 21177866]
- [102]. Baumkotter F, Schmidt N, Vargas C, Schilling S, Weber R, Wagner K, Fiedler S, Klug W, Radzimanowski J, Nickolaus S, Keller S, Eggert S, Wild K & Kins S (2014). Amyloid precursor protein dimerization and synaptogenic function depend on copper binding to the growth factor-like domain. *J Neurosci.* 34,11159–72. [PubMed: 25122912]
- [103]. Hung YH, Robb EL, Volitakis I, Ho M, Evin G, Li QX, Culvenor JG, Masters CL, Cherny RA & Bush AI (2009). Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions: Implications for alzheimer disease. *J Biol Chem.* 284,21899–907. [PubMed: 19542222]
- [104]. Noda Y, Asada M, Kubota M, Maesako M, Watanabe K, Uemura M, Kihara T, Shimohama S, Takahashi R, Kinoshita A & Uemura K (2013). Copper enhances app dimerization and promotes abeta production. *Neurosci Lett.* 547,10–5. [PubMed: 23669644]
- [105]. Spoerri L, Vella LJ, Pham CL, Barnham KJ & Cappai R (2012). The amyloid precursor protein copper binding domain histidine residues 149 and 151 mediate app stability and metabolism. *J Biol Chem.* 287,26840–53. [PubMed: 22685292]
- [106]. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE & Bush AI (2000). Characterization of copper interactions with alzheimer amyloid beta peptides: Identification of an attomolar-affinity copper binding site on amyloid beta1–42. *J Neurochem.* 75,1219–33. [PubMed: 10936205]
- [107]. Mayes J, Tinker-Mill C, Kolosov O, Zhang H, Tabner BJ & Allsop D (2014). Beta-amyloid fibrils in alzheimer disease are not inert when bound to copper ions but can degrade hydrogen peroxide and generate reactive oxygen species. *J Biol Chem.* 289,12052–62. [PubMed: 24619420]
- [108]. White AR, Multhaup G, Maher F, Bellingham S, Camakaris J, Zheng H, Bush AI, Beyreuther K, Masters CL & Cappai R (1999). The alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. *J Neurosci.* 19,9170–9. [PubMed: 10531420]
- [109]. Ma Q, Li Y, Du J, Liu H, Kanazawa K, Nemoto T, Nakanishi H & Zhao Y (2006). Copper binding properties of a tau peptide associated with alzheimer's disease studied by cd, nmr, and maldi-tof ms. *Peptides.* 27,841–9. [PubMed: 16225961]
- [110]. Ma QF, Li YM, Du JT, Kanazawa K, Nemoto T, Nakanishi H & Zhao YF (2005). Binding of copper (ii) ion to an alzheimer's tau peptide as revealed by maldi-tof ms, cd, and nmr. *Biopolymers.* 79,74–85. [PubMed: 15986501]
- [111]. Zhou LX, Du JT, Zeng ZY, Wu WH, Zhao YF, Kanazawa K, Ishizuka Y, Nemoto T, Nakanishi H & Li YM (2007). Copper (ii) modulates in vitro aggregation of a tau peptide. *Peptides.* 28,2229–34. [PubMed: 17919778]
- [112]. Su XY, Wu WH, Huang ZP, Hu J, Lei P, Yu CH, Zhao YF & Li YM (2007). Hydrogen peroxide can be generated by tau in the presence of cu(ii). *Biochem Biophys Res Commun.* 358,661–5. [PubMed: 17498655]
- [113]. Hu Z, Yu F, Gong P, Qiu Y, Zhou W, Cui Y, Li J & Chen H (2014). Subneurotoxic copper(ii)-induced nf-kappab-dependent microglial activation is associated with mitochondrial ros. *Toxicol Appl Pharmacol.* 276,95–103. [PubMed: 24530511]
- [114]. Yu F, Gong P, Hu Z, Qiu Y, Cui Y, Gao X, Chen H & Li J (2015). Cu(ii) enhances the effect of alzheimer's amyloid-beta peptide on microglial activation. *J Neuroinflammation.* 12,122. [PubMed: 26104799]
- [115]. Kitazawa M, Hsu HW & Medeiros R (2016). Copper exposure perturbs brain inflammatory responses and impairs clearance of amyloid-beta. *Toxicol Sci.* 152,194–204. [PubMed: 27122238]
- [116]. Lu J, Wu DM, Zheng YL, Sun DX, Hu B, Shan Q, Zhang ZF & Fan SH (2009). Trace amounts of copper exacerbate beta amyloid-induced neurotoxicity in the cholesterol-fed mice through tnf-mediated inflammatory pathway. *Brain Behav Immun.* 23,193–203. [PubMed: 18835350]

- [117]. Zheng Z, White C, Lee J, Peterson TS, Bush AI, Sun GY, Weisman GA & Petris MJ (2010). Altered microglial copper homeostasis in a mouse model of alzheimer's disease. *J Neurochem.* 114,1630–8. [PubMed: 20626553]
- [118]. Zucconi GG, Cipriani S, Scattoni R, Balgkouranidou I, Hawkins DP & Ragnarsdottir KV (2007). Copper deficiency elicits glial and neuronal response typical of neurodegenerative disorders. *Neuropathol Appl Neurobiol.* 33,212–25. [PubMed: 17359362]
- [119]. Rossi-George A & Guo CJ (2016). Copper disrupts s-nitrosothiol signaling in activated bv2 microglia. *Neurochem Int.* 99,1–8. [PubMed: 27216010]
- [120]. Rossi-George A, Guo CJ, Oakes BL & Gow AJ (2012). Copper modulates the phenotypic response of activated bv2 microglia through the release of nitric oxide. *Nitric Oxide.* 27,201–9. [PubMed: 22819698]
- [121]. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ & Bush AI (2008). Rapid restoration of cognition in alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial abeta. *Neuron.* 59,43–55. [PubMed: 18614028]
- [122]. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, Mclean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL & Bush AI (2001). Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in alzheimer's disease transgenic mice. *Neuron.* 30,665–76. [PubMed: 11430801]
- [123]. Cherny RA, Legg JT, Mclean CA, Fairlie DP, Huang X, Atwood CS, Beyreuther K, Tanzi RE, Masters CL & Bush AI (1999). Aqueous dissolution of alzheimer's disease abeta amyloid deposits by biometal depletion. *J Biol Chem.* 274,23223–8. [PubMed: 10438495]
- [124]. Grossi C, Francese S, Casini A, Rosi MC, Luccarini I, Fiorentini A, Gabbiani C, Messori L, Moneti G & Casamenti F (2009). Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of alzheimer's disease. *J Alzheimers Dis.* 17,423–40. [PubMed: 19363260]
- [125]. Matlack KE, Tardiff DF, Narayan P, Hamamichi S, Caldwell KA, Caldwell GA & Lindquist S (2014). Clioquinol promotes the degradation of metal-dependent amyloid-beta (abeta) oligomers to restore endocytosis and ameliorate abeta toxicity. *Proc Natl Acad Sci USA.* 111,4013–8. [PubMed: 24591589]
- [126]. Segal-Gavish H, Danino O, Barhum Y, Ben-Zur T, Shai E, Varon D, Offen D & Fischer B (2017). A multifunctional biocompatible drug candidate is highly effective in delaying pathological signs of alzheimer's disease in 5xfad mice. *J Alzheimers Dis.* 58,389–400. [PubMed: 28453480]
- [127]. Donnelly PS, Caragounis A, Du T, Laughton KM, Volitakis I, Cherny RA, Sharples RA, Hill AF, Li QX, Masters CL, Barnham KJ & White AR (2008). Selective intracellular release of copper and zinc ions from bis(thiosemicarbazone) complexes reduces levels of alzheimer disease amyloid-beta peptide. *J Biol Chem.* 283,4568–77. [PubMed: 18086681]
- [128]. Gerber H, Wu F, Dimitrov M, Garcia Osuna GM & Fraering PC (2017). Zinc and copper differentially modulate amyloid precursor protein processing by gamma-secretase and amyloid-beta peptide production. *J Biol Chem.* 292,3751–67. [PubMed: 28096459]
- [129]. Crouch PJ, Hung LW, Adlard PA, Cortes M, Lal V, Filiz G, Perez KA, Nurjono M, Caragounis A, Du T, Laughton K, Volitakis I, Bush AI, Li QX, Masters CL, Cappai R, Cherny RA, Donnelly PS, White AR & Barnham KJ (2009). Increasing cu bioavailability inhibits abeta oligomers and tau phosphorylation. *Proc Natl Acad Sci USA.* 106,381–6. [PubMed: 19122148]
- [130]. Choo XY, Liddell JR, Huuskonen MT, Grubman A, Moujalled D, Roberts J, Kysenius K, Patten L, Quek H, Oikari LE, Duncan C, James SA, Mcinnes LE, Hayne DJ, Donnelly PS, Pollari E, Vahatalo S, Lejavova K, Kettunen MI, Malm T, Koistinaho J, White AR & Kanninen KM (2018). Cu(ii)(atsm) attenuates neuroinflammation. *Front Neurosci.* 12,668. [PubMed: 30319344]
- [131]. Sparks DL, Friedland R, Petanceska S, Schreurs BG, Shi J, Perry G, Smith MA, Sharma A, Derosa S, Ziolkowski C & Stankovic G (2006). Trace copper levels in the drinking water, but not zinc or aluminum influence cns alzheimer-like pathology. *J Nutr Health Aging.* 10,247–54. [PubMed: 16886094]

- [132]. Sparks DL & Schreurs BG (2003). Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of alzheimer's disease. *Proc Natl Acad Sci U S A*. 100,11065–9. [PubMed: 12920183]
- [133]. Singh I, Sagare AP, Coma M, Perlmutter D, Gelein R, Bell RD, Deane RJ, Zhong E, Parisi M, Ciszewski J, Kasper RT & Deane R (2013). Low levels of copper disrupt brain amyloid-beta homeostasis by altering its production and clearance. *Proc Natl Acad Sci U S A*. 110,14771–6. [PubMed: 23959870]
- [134]. Kitazawa M, Cheng D & Laferla FM (2009). Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of ad. *J Neurochem*. 108,1550–60. [PubMed: 19183260]
- [135]. Yu J, Luo X, Xu H, Ma Q, Yuan J, Li X, Chang RC, Qu Z, Huang X, Zhuang Z, Liu J & Yang X (2015). Identification of the key molecules involved in chronic copper exposure-aggravated memory impairment in transgenic mice of alzheimer's disease using proteomic analysis. *J Alzheimers Dis*. 44,455–69. [PubMed: 25352456]
- [136]. Takeda A (2000). Movement of zinc and its functional significance in the brain. *Brain Res Brain Res Rev*. 34,137–48. [PubMed: 11113504]
- [137]. Takeda A (2001). Zinc homeostasis and functions of zinc in the brain. *Biometals*. 14,343–51. [PubMed: 11831464]
- [138]. Mocchegiani E, Giacconi R, Cipriano C, Muzzioli M, Fattoretti P, Bertoni-Freddari C, Isani G, Zambenedetti P & Zatta P (2001). Zinc-bound metallothioneins as potential biological markers of ageing. *Brain Res Bull*. 55,147–53. [PubMed: 11470310]
- [139]. Liuzzi JP & Cousins RJ (2004). Mammalian zinc transporters. *Annu Rev Nutr*. 24,151–72. [PubMed: 15189117]
- [140]. Kambe T, Tsuji T, Hashimoto A & Isumura N (2015). The physiological, biochemical, and molecular roles of zinc transporters in zinc homeostasis and metabolism. *Physiol Rev*. 95,749–84. [PubMed: 26084690]
- [141]. Frederickson CJ, Suh SW, Silva D, Frederickson CJ & Thompson RB (2000). Importance of zinc in the central nervous system: The zinc-containing neuron. *J Nutr*. 130,1471s–83s. [PubMed: 10801962]
- [142]. Paoletti P, Vergnano AM, Barbour B & Casado M (2009). Zinc at glutamatergic synapses. *Neuroscience*. 158,126–36. [PubMed: 18353558]
- [143]. Sensi SL, Paoletti P, Koh JY, Aizenman E, Bush AI & Hershfinkel M (2011). The neurophysiology and pathology of brain zinc. *J Neurosci*. 31,16076–85. [PubMed: 22072659]
- [144]. Smart TG, Hosie AM & Miller PS (2004). Zn<sup>2+</sup> ions: Modulators of excitatory and inhibitory synaptic activity. *Neuroscientist*. 10,432–42. [PubMed: 15359010]
- [145]. Frederickson CJ & Danscher G (1990). Zinc-containing neurons in hippocampus and related CNS structures. *Prog Brain Res*. 83,71–84. [PubMed: 2203108]
- [146]. Doraiswamy PM & Finefrock AE (2004). Metals in our minds: Therapeutic implications for neurodegenerative disorders. *Lancet Neurol*. 3,431–4. [PubMed: 15207800]
- [147]. Mocchegiani E, Bertoni-Freddari C, Marcellini F & Malavolta M (2005). Brain, aging and neurodegeneration: Role of zinc ion availability. *Prog Neurobiol*. 75,367–90. [PubMed: 15927345]
- [148]. Cuajungco MP & Lees GJ (1997). Zinc metabolism in the brain: Relevance to human neurodegenerative disorders. *Neurobiol Dis*. 4,137–69. [PubMed: 9361293]
- [149]. Frederickson CJ, Koh JY & Bush AI (2005). The neurobiology of zinc in health and disease. *Nat Rev Neurosci*. 6,449–62. [PubMed: 15891778]
- [150]. Lee MC, Yu WC, Shih YH, Chen CY, Guo ZH, Huang SJ, Chan JCC & Chen YR (2018). Zinc ion rapidly induces toxic, off-pathway amyloid-beta oligomers distinct from amyloid-beta derived diffusible ligands in alzheimer's disease. *Sci Rep*. 8,4772. [PubMed: 29555950]
- [151]. Bush AI, Pettingell WH, Multhaup G, D Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL & Tanzi RE (1994). Rapid induction of alzheimer a beta amyloid formation by zinc. *Science*. 265,1464–7. [PubMed: 8073293]
- [152]. Assaf SY & Chung SH (1984). Release of endogenous zn<sup>2+</sup> from brain tissue during activity. *Nature*. 308,734–6. [PubMed: 6717566]

- [153]. Bush AI & Tanzi RE (2002). The galvanization of beta-amyloid in alzheimer's disease. *Proc Natl Acad Sci U S A.* 99,7317–9. [PubMed: 12032279]
- [154]. Deshpande A, Kawai H, Metherate R, Glabe CG & Busciglio J (2009). A role for synaptic zinc in activity-dependent abeta oligomer formation and accumulation at excitatory synapses. *J Neurosci.* 29,4004–15. [PubMed: 19339596]
- [155]. Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B, Pollwein P, Beyreuther K & Masters CL (1993). A novel zinc(ii) binding site modulates the function of the beta a4 amyloid protein precursor of alzheimer's disease. *J Biol Chem.* 268,16109–12. [PubMed: 8344894]
- [156]. Maynard CJ, Bush AI, Masters CL, Cappai R & Li QX (2005). Metals and amyloid-beta in alzheimer's disease. *Int J Exp Pathol.* 86,147–59. [PubMed: 15910549]
- [157]. Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G & Frederickson CJ (2000). Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of alzheimer's diseased brains. *Brain Res.* 852,274–8. [PubMed: 10678753]
- [158]. Lee JY, Cole TB, Palmiter RD, Suh SW & Koh JY (2002). Contribution by synaptic zinc to the gender-disparate plaque formation in human swedish mutant app transgenic mice. *Proc Natl Acad Sci U S A.* 99,7705–10. [PubMed: 12032347]
- [159]. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K & Mcconlogue L (2000). High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. *J Neurosci.* 20,4050–8. [PubMed: 10818140]
- [160]. Takeda A, Tamano H, Tempaku M, Sasaki M, Uematsu C, Sato S, Kanazawa H, Datki ZL, Adlard PA & Bush AI (2017). Extracellular zn(2+) is essential for amyloid beta1–42-induced cognitive decline in the normal brain and its rescue. *J Neurosci.* 37,7253–62. [PubMed: 28652412]
- [161]. Adlard PA, Bica L, White AR, Nurjono M, Filiz G, Crouch PJ, Donnelly PS, Cappai R, Finkelstein DI & Bush AI (2011). Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of alzheimer's disease. *PLoS One.* 6,e17669. [PubMed: 21412423]
- [162]. Adlard PA, Parncutt J, Lal V, James S, Hare D, Doble P, Finkelstein DI & Bush AI (2015). Metal chaperones prevent zinc-mediated cognitive decline. *Neurobiol Dis.* 81,196–202. [PubMed: 25549871]
- [163]. Frazzini V, Granzotto A, Bomba M, Massetti N, Castelli V, D'aurora M, Punzi M, Iorio M, Mosca A, Delli Pizzi S, Gatta V, Cimini A & Sensi SL (2018). The pharmacological perturbation of brain zinc impairs bdnf-related signaling and the cognitive performances of young mice. *Sci Rep.* 8,9768. [PubMed: 29950603]
- [164]. Wall MJ (2005). A role for zinc in cerebellar synaptic transmission? *Cerebellum.* 4,224–9. [PubMed: 16321877]
- [165]. Railey AM, Groeber CM & Flinn JM (2011). The effect of metals on spatial memory in a transgenic mouse model of alzheimer's disease. *J Alzheimers Dis.* 24,375–81. [PubMed: 21239856]
- [166]. Stoltenberg M, Bush AI, Bach G, Smidt K, Larsen A, Rungby J, Lund S, Doering P & Danscher G (2007). Amyloid plaques arise from zinc-enriched cortical layers in app/ps1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. *Neuroscience.* 150,357–69. [PubMed: 17949919]
- [167]. Wang CY, Wang T, Zheng W, Zhao BL, Danscher G, Chen YH & Wang ZY (2010). Zinc overload enhances app cleavage and abeta deposition in the alzheimer mouse brain. *PLoS One.* 5,e15349. [PubMed: 21179415]
- [168]. Harris CJ, Voss K, Murchison C, Ralle M, Frahler K, Carter R, Rhoads A, Lind B, Robinson E & Quinn JF (2014). Oral zinc reduces amyloid burden in tg2576 mice. *J Alzheimers Dis.* 41,179–92. [PubMed: 24595193]
- [169]. Capasso M, Jeng JM, Malavolta M, Mocchegiani E & Sensi SL (2005). Zinc dyshomeostasis: A key modulator of neuronal injury. *J Alzheimers Dis.* 8,93–108; discussion 209–15. [PubMed: 16308478]

- [170]. Crouch PJ, Savva MS, Hung LW, Donnelly PS, Mot AI, Parker SJ, Greenough MA, Volitakis I, Adlard PA, Cherny RA, Masters CL, Bush AI, Barnham KJ & White AR (2011). The alzheimer's therapeutic pbt2 promotes amyloid-beta degradation and gsk3 phosphorylation via a metal chaperone activity. *J Neurochem.* 119,220–30. [PubMed: 21797865]
- [171]. Andradi E, Farkas E, Gawlik D, Rosick U & Bratter P (2000). Brain iron and zinc contents of german patients with alzheimer disease. *J Alzheimers Dis.* 2,17–26. [PubMed: 12214107]
- [172]. Corrigan FM, Reynolds GP & Ward NI (1993). Hippocampal tin, aluminum and zinc in alzheimer's disease. *Biometals.* 6,149–54. [PubMed: 8400761]
- [173]. Danscher G, Jensen KB, Frederickson CJ, Kemp K, Andreasen A, Juhl S, Stoltenberg M & Ravid R (1997). Increased amount of zinc in the hippocampus and amygdala of alzheimer's diseased brains: A proton-induced x-ray emission spectroscopic analysis of cryostat sections from autopsy material. *J Neurosci Methods.* 76,53–9. [PubMed: 9334939]
- [174]. Panayi AE, Spyrou NM, Iversen BS, White MA & Part P (2002). Determination of cadmium and zinc in alzheimer's brain tissue using inductively coupled plasma mass spectrometry. *J Neurol Sci.* 195,1–10. [PubMed: 11867068]
- [175]. Rulon LL, Robertson JD, Lovell MA, Deibel MA, Ehmann WD & Markesber WR (2000). Serum zinc levels and alzheimer's disease. *Biol Trace Elem Res.* 75,79–85. [PubMed: 11051598]
- [176]. An WL, Bjorkdahl C, Liu R, Cowburn RF, Winblad B & Pei JJ (2005). Mechanism of zinc-induced phosphorylation of p70 s6 kinase and glycogen synthase kinase 3beta in sh-sy5y neuroblastoma cells. *J Neurochem.* 92,1104–15. [PubMed: 15715661]
- [177]. Mo ZY, Zhu YZ, Zhu HL, Fan JB, Chen J & Liang Y (2009). Low micromolar zinc accelerates the fibrillization of human tau via bridging of cys-291 and cys-322. *J Biol Chem.* 284,34648–57. [PubMed: 19826005]
- [178]. Pei JJ, An WL, Zhou XW, Nishimura T, Norberg J, Benedikz E, Gotz J & Winblad B (2006). P70 s6 kinase mediates tau phosphorylation and synthesis. *FEBS Lett.* 580,107–14. [PubMed: 16364302]
- [179]. Sun XY, Wei YP, Xiong Y, Wang XC, Xie AJ, Wang XL, Yang Y, Wang Q, Lu YM, Liu R & Wang JZ (2012). Synaptic released zinc promotes tau hyperphosphorylation by inhibition of protein phosphatase 2a (pp2a). *J Biol Chem.* 287,11174–82. [PubMed: 22334661]
- [180]. Xiong Y, Jing XP, Zhou XW, Wang XL, Yang Y, Sun XY, Qiu M, Cao FY, Lu YM, Liu R & Wang JZ (2013). Zinc induces protein phosphatase 2a inactivation and tau hyperphosphorylation through src dependent pp2a (tyrosine 307) phosphorylation. *Neurobiol Aging.* 34,745–56. [PubMed: 22892311]
- [181]. Huang Y, Wu Z, Cao Y, Lang M, Lu B & Zhou B (2014). Zinc binding directly regulates tau toxicity independent of tau hyperphosphorylation. *Cell Rep.* 8,831–42. [PubMed: 25066125]
- [182]. Craven KM, Kochen WR, Hernandez CM & Flinn JM (2018). Zinc exacerbates tau pathology in a tau mouse model. *J Alzheimers Dis.* 64,617–30. [PubMed: 29914030]
- [183]. Sedjahtera A, Gunawan L, Bray L, Hung LW, Parsons J, Okamura N, Villemagne VL, Yanai K, Liu XM, Chan J, Bush AI, Finkelstein DI, Barnham KJ, Cherny RA & Adlard PA (2018). Targeting metals rescues the phenotype in an animal model of tauopathy. *Metallomics.* 10,1339–47. [PubMed: 30168573]
- [184]. Aizenman E, Stout AK, Hartnett KA, Dineley KE, McLaughlin B & Reynolds IJ (2000). Induction of neuronal apoptosis by thiol oxidation: Putative role of intracellular zinc release. *J Neurochem.* 75,1878–88. [PubMed: 11032877]
- [185]. Bossy-Wetzel E, Talantova MV, Lee WD, Scholzke MN, Harrop A, Mathews E, Gotz T, Han J, Ellisman MH, Perkins GA & Lipton SA (2004). Crosstalk between nitric oxide and zinc pathways to neuronal cell death involving mitochondrial dysfunction and p38-activated k+ channels. *Neuron.* 41,351–65. [PubMed: 14766175]
- [186]. Jomova K, Vondrakova D, Lawson M & Valko M (2010). Metals, oxidative stress and neurodegenerative disorders. *Mol Cell Biochem.* 345,91–104. [PubMed: 20730621]
- [187]. Sensi SL, Rapposelli IG, Frazzini V & Mascetra N (2008). Altered oxidant-mediated intraneuronal zinc mobilization in a triple transgenic mouse model of alzheimer's disease. *Exp Gerontol.* 43,488–92. [PubMed: 18068923]

- [188]. Sensi SL, Ton-That D, Sullivan PG, Jonas EA, Gee KR, Kaczmarek LK & Weiss JH (2003). Modulation of mitochondrial function by endogenous zn<sup>2+</sup> pools. *Proc Natl Acad Sci U S A*. 100,6157–62. [PubMed: 12724524]
- [189]. Ibs KH & Rink L (2003). Zinc-altered immune function. *J Nutr*. 133,1452s–6s. [PubMed: 12730441]
- [190]. Mohammadi E, Qujeq D, Taheri H & Hajian-Tilaki K (2017). Evaluation of serum trace element levels and superoxide dismutase activity in patients with inflammatory bowel disease: Translating basic research into clinical application. *Biol Trace Elem Res*. 177,235–40. [PubMed: 27864666]
- [191]. Kelly EJ, Quaife CJ, Froelick GJ & Palmiter RD (1996). Metallothionein i and ii protect against zinc deficiency and zinc toxicity in mice. *J Nutr*. 126,1782–90. [PubMed: 8683339]
- [192]. Wong CP, Magnusson KR & Ho E (2013). Increased inflammatory response in aged mice is associated with age-related zinc deficiency and zinc transporter dysregulation. *J Nutr Biochem*. 24,353–9. [PubMed: 22981370]
- [193]. Haase H & Rink L (2009). Functional significance of zinc-related signaling pathways in immune cells. *Annu Rev Nutr*. 29,133–52. [PubMed: 19400701]
- [194]. Kauppinen TM, Higashi Y, Suh SW, Escartin C, Nagasawa K & Swanson RA (2008). Zinc triggers microglial activation. *J Neurosci*. 28,5827–35. [PubMed: 18509044]
- [195]. Mocchegiani E, Burkle A & Fulop T (2008). Zinc and ageing (zincage project). *Exp Gerontol*. 43,361–2. [PubMed: 18417310]
- [196]. Giacconi R, Costarelli L, Piacenza F, Basso A, Rink L, Mariani E, Fulop T, Dedoussis G, Herbein G, Provinciali M, Jajte J, Lengyel I, Mocchegiani E & Malavolta M (2017). Main biomarkers associated with age-related plasma zinc decrease and copper/zinc ratio in healthy elderly from zincage study. *Eur J Nutr*. 56,2457–66. [PubMed: 27459881]
- [197]. Kahmann L, Uciechowski P, Warmuth S, Plumakers B, Gressner AM, Malavolta M, Mocchegiani E & Rink L (2008). Zinc supplementation in the elderly reduces spontaneous inflammatory cytokine release and restores t cell functions. *Rejuvenation Res*. 11,227–37. [PubMed: 18279033]
- [198]. Mocchegiani E, Malavolta M, Costarelli L, Giacconi R, Cipriano C, Piacenza F, Tesi S, Basso A, Pierpaoli S & Lattanzio F (2010). Zinc, metallothioneins and immunosenescence. *Proc Nutr Soc*. 69,290–9. [PubMed: 20579408]
- [199]. Brewer GJ (2012). Copper excess, zinc deficiency, and cognition loss in alzheimer’s disease. *Biofactors*. 38,107–13. [PubMed: 22438177]
- [200]. Mocchegiani E, Romeo J, Malavolta M, Costarelli L, Giacconi R, Diaz LE & Marcos A (2013). Zinc: Dietary intake and impact of supplementation on immune function in elderly. *Age (Dordr)*. 35,839–60. [PubMed: 22222917]
- [201]. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J & Ritchie CW (2008). Safety, efficacy, and biomarker findings of pbt2 in targeting abeta as a modifying therapy for alzheimer’s disease: A phase iia, double-blind, randomised, placebo-controlled trial. *Lancet Neurol*. 7,779–86. [PubMed: 18672400]
- [202]. Parikh SR, Hurwitz RA, Hubbard JE, Brown JW, King H & Girod DA (1991). Preoperative and postoperative “aneurysm” associated with coarctation of the aorta. *J Am Coll Cardiol*. 17,1367–72. [PubMed: 2016456]
- [203]. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, Macgregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE & Masters CL (2003). Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting abeta amyloid deposition and toxicity in alzheimer disease: A pilot phase 2 clinical trial. *Arch Neurol*. 60,1685–91. [PubMed: 14676042]
- [204]. Corona C, Frazzini V, Silvestri E, Lattanzio R, La Sorda R, Piantelli M, Canzoniero LM, Ciavardelli D, Rizzarelli E & Sensi SL (2011). Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xtg-ad mice. *PLoS One*. 6,e17971. [PubMed: 21423579]
- [205]. Corona C, Masciopinto F, Silvestri E, Viscovo AD, Lattanzio R, Sorda RL, Ciavardelli D, Goglia F, Piantelli M, Canzoniero LM & Sensi SL (2010). Dietary zinc supplementation of 3xtg-

- ad mice increases bdnf levels and prevents cognitive deficits as well as mitochondrial dysfunction. *Cell Death Dis.* 1,e91. [PubMed: 21368864]
- [206]. Bryan MR & Bowman AB (2017). Manganese and the insulin-igf signaling network in huntington's disease and other neurodegenerative disorders. *Adv Neurobiol.* 18,113–42. [PubMed: 28889265]
- [207]. Caudle WM (2017). Occupational metal exposure and parkinsonism. *Adv Neurobiol.* 18,143–58. [PubMed: 28889266]
- [208]. Lucchini R, Placidi D, Cagna G, Fedrighi C, Oppini M, Peli M & Zoni S (2017). Manganese and developmental neurotoxicity. *Adv Neurobiol.* 18,13–34. [PubMed: 28889261]
- [209]. Zogzas CE & Mukhopadhyay S (2017). Inherited disorders of manganese metabolism. *Adv Neurobiol.* 18,35–49. [PubMed: 28889262]
- [210]. Chtourou Y, Trabelsi K, Fetoui H, Mkannez G, Kallel H & Zeghal N (2011). Manganese induces oxidative stress, redox state unbalance and disrupts membrane bound atpases on murine neuroblastoma cells in vitro: Protective role of silymarin. *Neurochem Res.* 36,1546–57. [PubMed: 21533646]
- [211]. Fitsanakis VA, Au C, Erikson KM & Aschner M (2006). The effects of manganese on glutamate, dopamine and gamma-aminobutyric acid regulation. *Neurochem Int.* 48,426–33. [PubMed: 16513220]
- [212]. Kwik-Urbe C & Smith DR (2006). Temporal responses in the disruption of iron regulation by manganese. *J Neurosci Res.* 83,1601–10. [PubMed: 16568477]
- [213]. Milatovic D, Yin Z, Gupta RC, Sidoryk M, Albrecht J, Aschner JL & Aschner M (2007). Manganese induces oxidative impairment in cultured rat astrocytes. *Toxicol Sci.* 98,198–205. [PubMed: 17468184]
- [214]. Tamm C, Sabri F & Ceccatelli S (2008). Mitochondrial-mediated apoptosis in neural stem cells exposed to manganese. *Toxicol Sci.* 101,310–20. [PubMed: 17977900]
- [215]. Kirkley KS, Popichak KA, Afzali MF, Legare ME & Tjalkens RB (2017). Microglia amplify inflammatory activation of astrocytes in manganese neurotoxicity. *J Neuroinflammation.* 14,99. [PubMed: 28476157]
- [216]. Tjalkens RB, Popichak KA & Kirkley KA (2017). Inflammatory activation of microglia and astrocytes in manganese neurotoxicity. *Adv Neurobiol.* 18,159–81. [PubMed: 28889267]
- [217]. Wang D, Zhang J, Jiang W, Cao Z, Zhao F, Cai T, Aschner M & Luo W (2017). The role of nlrp3-casp1 in inflammasome-mediated neuroinflammation and autophagy dysfunction in manganese-induced, hippocampal-dependent impairment of learning and memory ability. *Autophagy.* 13,914–27. [PubMed: 28318352]
- [218]. Markesbery WR, Ehmann WD, Hossain TI & Alauddin M (1984). Brain manganese concentrations in human aging and alzheimer's disease. *Neurotoxicology.* 5,49–57. [PubMed: 6538949]
- [219]. Du K, Liu M, Pan Y, Zhong X & Wei M (2017). Association of serum manganese levels with alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis. *Nutrients.* 9.
- [220]. Wallin C, Kulkarni YS, Abelein A, Jarvet J, Liao Q, Strodel B, Olsson L, Luo J, Abrahams JP, Sholts SB, Roos PM, Kamerlin SC, Graslund A & Warmlander SK (2016). Characterization of mn(ii) ion binding to the amyloid-beta peptide in alzheimer's disease. *J Trace Elem Med Biol.* 38,183–93. [PubMed: 27085215]
- [221]. Guilarte TR, Burton NC, Verina T, Prabhu VV, Becker KG, Syversen T & Schneider JS (2008). Increased aplp1 expression and neurodegeneration in the frontal cortex of manganese-exposed non-human primates. *J Neurochem.* 105,1948–59. [PubMed: 18284614]
- [222]. Schneider JS, Williams C, Ault M & Guilarte TR (2013). Chronic manganese exposure impairs visuospatial associative learning in non-human primates. *Toxicol Lett.* 221,146–51. [PubMed: 23778301]
- [223]. Venkataramani V, Doeppner TR, Willkommen D, Cahill CM, Xin Y, Ye G, Liu Y, Southon A, Aron A, Au-Yeung HY, Huang X, Lahiri DK, Wang F, Bush AI, Wulf GG, Strobel P, Michalke B & Rogers JT (2018). Manganese causes neurotoxic iron accumulation via translational repression of amyloid precursor protein (app) and h-ferritin. *J Neurochem.*



- [224]. Sidoryk-Wegrzynowicz M, Lee E & Aschner M (2012). Mechanism of mn(ii)-mediated dysregulation of glutamine-glutamate cycle: Focus on glutamate turnover. *J Neurochem.* 122,856–67. [PubMed: 22708868]
- [225]. Ling J, Yang S, Huang Y, Wei D & Cheng W (2018). Identifying key genes, pathways and screening therapeutic agents for manganese-induced alzheimer disease using bioinformatics analysis. *Medicine (Baltimore).* 97,e10775. [PubMed: 29851783]
- [226]. Needleman H (2009). Low level lead exposure: History and discovery. *Ann Epidemiol.* 19,235–8. [PubMed: 19344860]
- [227]. Nash D, Magder LS, Sherwin R, Rubin RJ & Silbergeld EK (2004). Bone density-related predictors of blood lead level among peri- and postmenopausal women in the united states: The third national health and nutrition examination survey, 1988–1994. *Am J Epidemiol.* 160,901–11. [PubMed: 15496543]
- [228]. Rastogi S, Nandlike K & Fenster W (2007). Elevated blood lead levels in pregnant women: Identification of a high-risk population and interventions. *J Perinat Med.* 35,492–6. [PubMed: 18052836]
- [229]. Tellez-Rojo MM, Hernandez-Avila M, Gonzalez-Cossio T, Romieu I, Aro A, Palazuelos E, Schwartz J & Hu H (2002). Impact of breastfeeding on the mobilization of lead from bone. *Am J Epidemiol.* 155,420–8. [PubMed: 11867353]
- [230]. Brubaker CJ, Schmithorst VJ, Haynes EN, Dietrich KN, Egelhoff JC, Lindquist DM, Lanphear BP & Cecil KM (2009). Altered myelination and axonal integrity in adults with childhood lead exposure: A diffusion tensor imaging study. *Neurotoxicology.* 30,867–75.
- [231]. Hu F, Xu L, Liu ZH, Ge MM, Ruan DY & Wang HL (2014). Developmental lead exposure alters synaptogenesis through inhibiting canonical wnt pathway in vivo and in vitro. *PLoS One.* 9,e101894. [PubMed: 24999626]
- [232]. Senut MC, Sen A, Cingolani P, Shaik A, Land SJ & Ruden DM (2014). Lead exposure disrupts global DNA methylation in human embryonic stem cells and alters their neuronal differentiation. *Toxicol Sci.* 139,142–61. [PubMed: 24519525]
- [233]. Li S, Liu XL, Zhou XL, Jiang SJ & Yuan H (2015). Expression of calmodulin-related genes in lead-exposed mice. *Interdiscip Toxicol.* 8,155–8. [PubMed: 27486376]
- [234]. Sanders T, Liu Y, Buchner V & Tchounwou PB (2009). Neurotoxic effects and biomarkers of lead exposure: A review. *Rev Environ Health.* 24,15–45. [PubMed: 19476290]
- [235]. Bijoer AR, Sudha S & Venkatesh T (2012). Neurochemical and neurobehavioral effects of low lead exposure on the developing brain. *Indian J Clin Biochem.* 27,147–51. [PubMed: 23543765]
- [236]. Stansfield KH, Ruby KN, Soares BD, Mcglothlan JL, Liu X & Guilarte TR (2015). Early-life lead exposure recapitulates the selective loss of parvalbumin-positive gabaergic interneurons and subcortical dopamine system hyperactivity present in schizophrenia. *Transl Psychiatry.* 5,e522. [PubMed: 25756805]
- [237]. Flora G, Gupta D & Tiwari A (2012). Toxicity of lead: A review with recent updates. *Interdiscip Toxicol.* 5,47–58. [PubMed: 23118587]
- [238]. Mazumdar M, Bellinger DC, Gregas M, Abanilla K, Bacic J & Needleman HL (2011). Low-level environmental lead exposure in childhood and adult intellectual function: A follow-up study. *Environ Health.* 10,24. [PubMed: 21450073]
- [239]. Reuben A, Caspi A, Belsky DW, Broadbent J, Harrington H, Sugden K, Houts RM, Ramrakha S, Poulton R & Moffitt TE (2017). Association of childhood blood lead levels with cognitive function and socioeconomic status at age 38 years and with iq change and socioeconomic mobility between childhood and adulthood. *Jama.* 317,1244–51. [PubMed: 28350927]
- [240]. Wang T, Guan RL, Liu MC, Shen XF, Chen JY, Zhao MG & Luo WJ (2016). Lead exposure impairs hippocampus related learning and memory by altering synaptic plasticity and morphology during juvenile period. *Mol Neurobiol.* 53,3740–52. [PubMed: 26141123]
- [241]. Bihagi SW, Bahmani A, Adem A & Zawia NH (2014). Infantile postnatal exposure to lead (pb) enhances tau expression in the cerebral cortex of aged mice: Relevance to ad. *Neurotoxicology.* 44,114–20. [PubMed: 24954411]

- [242]. Hu Q, Fu H, Ren T, Wang S, Zhou W, Song H, Han Y & Dong S (2008). Maternal low-level lead exposure reduces the expression of *psa-ncam* and the activity of sialyltransferase in the hippocampi of neonatal rat pups. *Neurotoxicology*. 29,675–81. [PubMed: 18499259]
- [243]. Zhao ZH, Zheng G, Wang T, Du KJ, Han X, Luo WJ, Shen XF & Chen JY (2018). Low-level gestational lead exposure alters dendritic spine plasticity in the hippocampus and reduces learning and memory in rats. *Sci Rep*. 8,3533. [PubMed: 29476096]
- [244]. Schwartz BS, Stewart WF, Bolla KI, Simon PD, Bandeen-Roche K, Gordon PB, Links JM & Todd AC (2000). Past adult lead exposure is associated with longitudinal decline in cognitive function. *Neurology*. 55,1144–50. [PubMed: 11071492]
- [245]. Stewart WF, Schwartz BS, Davatzikos C, Shen D, Liu D, Wu X, Todd AC, Shi W, Bassett S & Youssef D (2006). Past adult lead exposure is linked to neurodegeneration measured by brain mri. *Neurology*. 66,1476–84. [PubMed: 16717205]
- [246]. Zhou CC, Gao ZY, Wang J, Wu MQ, Hu S, Chen F, Liu JX, Pan H & Yan CH (2018). Lead exposure induces alzheimer's disease (ad)-like pathology and disturbs cholesterol metabolism in the young rat brain. *Toxicol Lett*. 296,173–83. [PubMed: 29908845]
- [247]. Basha MR, Murali M, Siddiqi HK, Ghosal K, Siddiqi OK, Lashuel HA, Ge YW, Lahiri DK & Zawia NH (2005). Lead (pb) exposure and its effect on app proteolysis and abeta aggregation. *Faseb j*. 19,2083–4. [PubMed: 16230335]
- [248]. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, Mcpherson CA, Harry J, Rice DC, Maloney B, Chen D, Lahiri DK & Zawia NH (2008). Alzheimer's disease (ad)-like pathology in aged monkeys after infantile exposure to environmental metal lead (pb): Evidence for a developmental origin and environmental link for ad. *J Neurosci*. 28,3–9. [PubMed: 18171917]
- [249]. Ashok A, Rai NK, Tripathi S & Bandyopadhyay S (2015). Exposure to as-, cd-, and pb-mixture induces abeta, amyloidogenic app processing and cognitive impairments via oxidative stress-dependent neuroinflammation in young rats. *Toxicol Sci*. 143,64–80. [PubMed: 25288670]
- [250]. Giudetti AM, Romano A, Lavecchia AM & Gaetani S (2016). The role of brain cholesterol and its oxidized products in alzheimer's disease. *Curr Alzheimer Res*. 13,198–205. [PubMed: 26391039]
- [251]. Gu H, Wei X, Monnot AD, Fontanilla CV, Behl M, Farlow MR, Zheng W & Du Y (2011). Lead exposure increases levels of beta-amyloid in the brain and csf and inhibits *lrp1* expression in app transgenic mice. *Neurosci Lett*. 490,16–20. [PubMed: 21167913]
- [252]. Bihaqi SW, Eid A & Zawia NH (2017). Lead exposure and tau hyperphosphorylation: An in vitro study. *Neurotoxicology*. 62,218–23. [PubMed: 28765091]
- [253]. Bihaqi SW & Zawia NH (2013). Enhanced tauopathy and ad-like pathology in aged primate brains decades after infantile exposure to lead (pb). *Neurotoxicology*. 39,95–101. [PubMed: 23973560]
- [254]. Bihaqi SW, Alansi B, Masoud AM, Mushtaq F, Subaiea GM & Zawia NH (2018). Influence of early life lead (pb) exposure on alpha-synuclein, gsk-3beta and caspase-3 mediated tauopathy: Implications on alzheimer's disease. *Curr Alzheimer Res*. 15,1114–22. [PubMed: 30068273]
- [255]. Di Lorenzo L, Vacca A, Corfiati M, Lovreglio P & Soleo L (2007). Evaluation of tumor necrosis factor-alpha and granulocyte colony-stimulating factor serum levels in lead-exposed smoker workers. *Int J Immunopathol Pharmacol*. 20,239–47. [PubMed: 17624258]
- [256]. Petrini M, Azzara A, Polidori R, Vatteroni ML, Caracciolo F, Carulli G & Ambrogi F (1982). Serum factors inhibiting some leukocytic functions in hodgkin's disease. *Clin Immunol Immunopathol*. 23,124–32. [PubMed: 7047031]
- [257]. Liu MC, Liu XQ, Wang W, Shen XF, Che HL, Guo YY, Zhao MG, Chen JY & Luo WJ (2012). Involvement of microglia activation in the lead induced long-term potentiation impairment. *PLoS One*. 7,e43924. [PubMed: 22952811]
- [258]. Kumawat KL, Kaushik DK, Goswami P & Basu A (2014). Acute exposure to lead acetate activates microglia and induces subsequent bystander neuronal death via caspase-3 activation. *Neurotoxicology*. 41,143–53. [PubMed: 24530660]
- [259]. Liu JT, Chen BY, Zhang JQ, Kuang F & Chen LW (2015). Lead exposure induced microgliosis and astrogliosis in hippocampus of young mice potentially by triggering *tlr4-myd88-nf-kappab* signaling cascades. *Toxicol Lett*. 239,97–107. [PubMed: 26386401]


- [260]. Majewska M & Szczepanik M (2006). [the role of toll-like receptors (tlr) in innate and adaptive immune responses and their function in immune response regulation]. *Postepy Hig Med Dosw (Online)*. 60,52–63. [PubMed: 16474276]
- [261]. Altmann P, Cunningham J, Dhanesha U, Ballard M, Thompson J & Marsh F (1999). Disturbance of cerebral function in people exposed to drinking water contaminated with aluminium sulphate: Retrospective study of the camelford water incident. *Bmj*. 319,807–11. [PubMed: 10496822]
- [262]. Priest ND (2004). The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: Review and study update. *J Environ Monit*. 6,375–403. [PubMed: 15152306]
- [263]. Yumoto S, Nagai H, Kobayashi K, Tamate A, Kakimi S & Matsuzaki H (2003). 26al incorporation into the brain of suckling rats through maternal milk. *J Inorg Biochem*. 97,155–60. [PubMed: 14507472]
- [264]. Kawahara M & Kato-Negishi M (2011). Link between aluminum and the pathogenesis of alzheimer's disease: The integration of the aluminum and amyloid cascade hypotheses. *Int J Alzheimers Dis*. 2011,276393. [PubMed: 21423554]
- [265]. Colomina MT & Peris-Sampedro F (2017). Aluminum and alzheimer's disease. *Adv Neurobiol*. 18,183–97. [PubMed: 28889268]
- [266]. Singla N & Dhawan DK (2012). Regulatory role of zinc during aluminium-induced altered carbohydrate metabolism in rat brain. *J Neurosci Res*. 90,698–705. [PubMed: 22108899]
- [267]. Yokel RA & Mcnamara PJ (2001). Aluminium toxicokinetics: An updated minireview. *Pharmacol Toxicol*. 88,159–67. [PubMed: 11322172]
- [268]. Muma NA & Singer SM (1996). Aluminum-induced neuropathology: Transient changes in microtubule-associated proteins. *Neurotoxicol Teratol*. 18,679–90. [PubMed: 8947945]
- [269]. Colomina MT, Roig JL, Sanchez DJ & Domingo JL (2002). Influence of age on aluminum-induced neurobehavioral effects and morphological changes in rat brain. *Neurotoxicology*. 23,775–81. [PubMed: 12520767]
- [270]. Shafer TJ & Mundy WR (1995). Effects of aluminum on neuronal signal transduction: Mechanisms underlying disruption of phosphoinositide hydrolysis. *Gen Pharmacol*. 26,889–95. [PubMed: 7557263]
- [271]. Walton JR (2012). Aluminum disruption of calcium homeostasis and signal transduction resembles change that occurs in aging and alzheimer's disease. *J Alzheimers Dis*. 29,255–73. [PubMed: 22330830]
- [272]. Kaji R, Izumi Y, Adachi Y & Kuzuhara S (2012). Als-parkinsonism-dementia complex of kii and other related diseases in japan. *Parkinsonism Relat Disord*. 18 Suppl 1,S190–1. [PubMed: 22166431]
- [273]. Flaten TP (2001). Aluminium as a risk factor in alzheimer's disease, with emphasis on drinking water. *Brain Res Bull*. 55,187–96. [PubMed: 11470314]
- [274]. Forbes WF & Mclachlan DR (1996). Further thoughts on the aluminum-alzheimer's disease link. *J Epidemiol Community Health*. 50,401–3. [PubMed: 8882222]
- [275]. Martyn CN, Barker DJ, Osmond C, Harris EC, Edwardson JA & Lacey RF (1989). Geographical relation between alzheimer's disease and aluminum in drinking water. *Lancet*. 1,59–62. [PubMed: 2562879]
- [276]. Neri LC & Hewitt D (1991). Aluminium, alzheimer's disease, and drinking water. *Lancet*. 338,390.
- [277]. O'farrell EK (1975). Write for the reader, he may need to know what you have to say. *Can Nurse*. 71,24–7.
- [278]. Boni UD, Otvos A, Scott JW & Crapper DR (1976). Neurofibrillary degeneration induced by systemic aluminum. *Acta Neuropathol*. 35,285–94. [PubMed: 961381]
- [279]. Kihira T, Yoshida S, Yase Y, Ono S & Kondo T (2002). Chronic low-ca/mg high-al diet induces neuronal loss. *Neuropathology*. 22,171–9. [PubMed: 12416556]
- [280]. Klatzo I, Wisniewski H & Streicher E (1965). Experimental production of neurofibrillary degeneration. I. Light microscopic observations. *J Neuropathol Exp Neurol*. 24,187–99. [PubMed: 14280496]

- [281]. Savory J, Huang Y, Herman MM, Reyes MR & Wills MR (1995). Tau immunoreactivity associated with aluminum maltolate-induced neurofibrillary degeneration in rabbits. *Brain Res.* 669,325–9. [PubMed: 7712190]
- [282]. Bouras C, Giannakopoulos P, Good PF, Hsu A, Hof PR & Perl DP (1997). A laser microprobe mass analysis of brain aluminum and iron in dementia pugilistica: Comparison with alzheimer's disease. *Eur Neurol.* 38,53–8. [PubMed: 9252800]
- [283]. Crapper DR, Krishnan SS & Dalton AJ (1973). Brain aluminum distribution in alzheimer's disease and experimental neurofibrillary degeneration. *Science.* 180,511–3. [PubMed: 4735595]
- [284]. Mcdermott JR, Smith AI, Iqbal K & Wisniewski HM (1979). Brain aluminum in aging and alzheimer disease. *Neurology.* 29,809–14. [PubMed: 572003]
- [285]. Oshima E, Ishihara T, Yokota O, Nakashima-Yasuda H, Nagao S, Ikeda C, Naohara J, Terada S & Uchitomi Y (2013). Accelerated tau aggregation, apoptosis and neurological dysfunction caused by chronic oral administration of aluminum in a mouse model of tauopathies. *Brain Pathol.* 23,633–44. [PubMed: 23574527]
- [286]. Amador FC, Henriques AG, Da Cruz ESOA & Da Cruz ESEF (2004). Monitoring protein phosphatase 1 isoform levels as a marker for cellular stress. *Neurotoxicol Teratol.* 26,387–95. [PubMed: 15113600]
- [287]. Huang W, Cheng P, Yu K, Han Y, Song M & Li Y (2017). Hyperforin attenuates aluminum-induced abeta production and tau phosphorylation via regulating akt/gsk-3beta signaling pathway in pc12 cells. *Biomed Pharmacother.* 96,1–6. [PubMed: 28961505]
- [288]. Nubling G, Bader B, Levin J, Hildebrandt J, Kretzschmar H & Giese A (2012). Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with alpha-synuclein at the single molecule level. *Mol Neurodegener.* 7,35. [PubMed: 22824345]
- [289]. Scott CW, Fieles A, Sygowski LA & Caputo CB (1993). Aggregation of tau protein by aluminum. *Brain Res.* 628,77–84. [PubMed: 8313173]
- [290]. Yamamoto H, Saitoh Y, Yasugawa S & Miyamoto E (1990). Dephosphorylation of tau factor by protein phosphatase 2a in synaptosomal cytosol fractions, and inhibition by aluminum. *J Neurochem.* 55,683–90. [PubMed: 2164575]
- [291]. Akiyama H, Hosokawa M, Kametani F, Kondo H, Chiba M, Fukushima M & Tabira T (2012). Long-term oral intake of aluminium or zinc does not accelerate alzheimer pathology in abetapp and abetapp/tau transgenic mice. *Neuropathology.* 32,390–7. [PubMed: 22118300]
- [292]. Zielke HR, Jackson MJ, Tildon JT & Max SR (1993). A glutamatergic mechanism for aluminum toxicity in astrocytes. *Mol Chem Neuropathol.* 19,219–33. [PubMed: 8104402]
- [293]. Helber A, Dvorak K, Winkelmann W, Meurer KA, Wurz H & Dickmans A (1975). [131i-cholesterol scanning of the adrenals: Results in various adrenal diseases, especially unilateral adrenal tumours (author's transl)]. *Dtsch Med Wochenschr.* 100,2524–7. [PubMed: 1192963]
- [294]. Quintanilla RA, Orellana DI, Gonzalez-Billault C & Maccioni RB (2004). Interleukin-6 induces alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. *Exp Cell Res.* 295,245–57. [PubMed: 15051507]
- [295]. Akinrinade ID, Memudu AE, Ogundele OM & Ajetunmobi OI (2015). Interplay of glia activation and oxidative stress formation in fluoride and aluminium exposure. *Pathophysiology.* 22,39–48. [PubMed: 25577494]
- [296]. Exley C, Price NC, Kelly SM & Birchall JD (1993). An interaction of beta-amyloid with aluminium in vitro. *FEBS Lett.* 324,293–5. [PubMed: 8405368]
- [297]. Luo Y, Niu F, Sun Z, Cao W, Zhang X, Guan D, Lv Z, Zhang B & Xu Y (2009). Altered expression of abeta metabolism-associated molecules from d-galactose/alcl(3) induced mouse brain. *Mech Ageing Dev.* 130,248–52. [PubMed: 19150622]
- [298]. Mantyh PW, Ghilardi JR, Rogers S, Demaster E, Allen CJ, Stimson ER & Maggio JE (1993). Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. *J Neurochem.* 61,1171–4. [PubMed: 8360682]
- [299]. Sakamoto T, Saito H, Ishii K, Takahashi H, Tanabe S & Ogasawara Y (2006). Aluminum inhibits proteolytic degradation of amyloid beta peptide by cathepsin d: A potential link between aluminum accumulation and neuritic plaque deposition. *FEBS Lett.* 580,6543–9. [PubMed: 17112520]

- [300]. Pratico D, Uryu K, Sung S, Tang S, Trojanowski JQ & Lee VM (2002). Aluminum modulates brain amyloidosis through oxidative stress in app transgenic mice. *Faseb j.* 16,1138–40. [PubMed: 12039845]
- [301]. Drago D, Bolognin S & Zatta P (2008). Role of metal ions in the abeta oligomerization in alzheimer's disease and in other neurological disorders. *Curr Alzheimer Res.* 5,500–7. [PubMed: 19075576]
- [302]. Drago D, Cavaliere A, Mascetra N, Ciavardelli D, Di Ilio C, Zatta P & Sensi SL (2008). Aluminum modulates effects of beta amyloid(1–42) on neuronal calcium homeostasis and mitochondria functioning and is altered in a triple transgenic mouse model of alzheimer's disease. *Rejuvenation Res.* 11,861–71. [PubMed: 18788899]
- [303]. Ricchelli F, Drago D, Filippi B, Tognon G & Zatta P (2005). Aluminum-triggered structural modifications and aggregation of beta-amyloids. *Cell Mol Life Sci.* 62,1724–33. [PubMed: 15990957]
- [304]. Oshiro S, Kawahara M, Mika S, Muramoto K, Kobayashi K, Ishige R, Nozawa K, Hori M, Yung C, Kitajima S & Kuroda Y (1998). Aluminum taken up by transferrin-independent iron uptake affects the iron metabolism in rat cortical cells. *J Biochem.* 123,42–6. [PubMed: 9504407]
- [305]. Yamanaka K, Minato N & Iwai K (1999). Stabilization of iron regulatory protein 2, irp2, by aluminum. *FEBS Lett.* 462,216–20. [PubMed: 10580122]
- [306]. Lin R, Chen X, Li W, Han Y, Liu P & Pi R (2008). Exposure to metal ions regulates mrna levels of app and bace1 in pc12 cells: Blockage by curcumin. *Neurosci Lett.* 440,344–7. [PubMed: 18583042]
- [307]. Walton JR & Wang MX (2009). App expression, distribution and accumulation are altered by aluminum in a rodent model for alzheimer's disease. *J Inorg Biochem.* 103,1548–54. [PubMed: 19818510]
- [308]. Kaneko N, Sugioka T & Sakurai H (2007). Aluminum compounds enhance lipid peroxidation in liposomes: Insight into cellular damage caused by oxidative stress. *J Inorg Biochem.* 101,967–75. [PubMed: 17467804]
- [309]. Kim Y, Olivi L, Cheong JH, Maertens A & Bressler JP (2007). Aluminum stimulates uptake of non-transferrin bound iron and transferrin bound iron in human glial cells. *Toxicol Appl Pharmacol.* 220,349–56. [PubMed: 17376497]
- [310]. Oteiza PI (1994). A mechanism for the stimulatory effect of aluminum on iron-induced lipid peroxidation. *Arch Biochem Biophys.* 308,374–9. [PubMed: 8109967]
- [311]. Exley C (2004). The pro-oxidant activity of aluminum. *Free Radic Biol Med.* 36,380–7. [PubMed: 15036357]
- [312]. Yuan CY, Lee YJ & Hsu GS (2012). Aluminum overload increases oxidative stress in four functional brain areas of neonatal rats. *J Biomed Sci.* 19,51. [PubMed: 22613782]
- [313]. Wu Z, Du Y, Xue H, Wu Y & Zhou B (2012). Aluminum induces neurodegeneration and its toxicity arises from increased iron accumulation and reactive oxygen species (ros) production. *Neurobiol Aging.* 33,199.e1–12.
- [314]. Fattoretti P, Bertoni-Freddari C, Baliotti M, Mocchegiani E, Scancar J, Zambenedetti P & Zatta P (2003). The effect of chronic aluminum(iii) administration on the nervous system of aged rats: Clues to understand its suggested role in alzheimer's disease. *J Alzheimers Dis.* 5,437–44. [PubMed: 14757933]
- [315]. Sanchez-Iglesias S, Mendez-Alvarez E, Iglesias-Gonzalez J, Munoz-Patino A, Sanchez-Sellero I, Labandeira-Garcia JL & Soto-Otero R (2009). Brain oxidative stress and selective behaviour of aluminium in specific areas of rat brain: Potential effects in a 6-ohda-induced model of parkinson's disease. *J Neurochem.* 109,879–88. [PubMed: 19425176]
- [316]. Ghribi O, Herman MM, Forbes MS, Dewitt DA & Savory J (2001). Gdnf protects against aluminum-induced apoptosis in rabbits by upregulating bcl-2 and bcl-xl and inhibiting mitochondrial bax translocation. *Neurobiol Dis.* 8,764–73. [PubMed: 11592846]
- [317]. Johnson VJ & Sharma RP (2003). Aluminum disrupts the pro-inflammatory cytokine/neurotrophin balance in primary brain rotation-mediated aggregate cultures: Possible role in neurodegeneration. *Neurotoxicology.* 24,261–8. [PubMed: 12606298]

- [318]. Kawahara M (2010). Neurotoxicity of beta-amyloid protein: Oligomerization, channel formation, and calcium dyshomeostasis. *Curr Pharm Des.* 16,2779–89. [PubMed: 20698821]
- [319]. Abu-Taweel GM, Ajarem JS & Ahmad M (2012). Neurobehavioral toxic effects of perinatal oral exposure to aluminum on the developmental motor reflexes, learning, memory and brain neurotransmitters of mice offspring. *Pharmacol Biochem Behav.* 101,49–56. [PubMed: 22115621]
- [320]. Liu YQ, Xin TR, Liang JJ, Wang WM & Zhang YY (2010). Memory performance, brain excitatory amino acid and acetylcholinesterase activity of chronically aluminum exposed mice in response to soy isoflavones treatment. *Phytother Res.* 24,1451–6. [PubMed: 20878693]
- [321]. Hefti F & Weiner WJ (1986). Nerve growth factor and alzheimer's disease. *Ann Neurol.* 20,275–81. [PubMed: 3532929]
- [322]. Yellamma K, Saraswathamma S & Kumari BN (2010). Cholinergic system under aluminium toxicity in rat brain. *Toxicol Int.* 17,106–12. [PubMed: 21170257]
- [323]. Hegde ML, Bharathi P, Suram A, Venugopal C, Jagannathan R, Poddar P, Srinivas P, Sambamurti K, Rao KJ, Scancar J, Messori L, Zecca L & Zatta P (2009). Challenges associated with metal chelation therapy in alzheimer's disease. *J Alzheimers Dis.* 17,457–68. [PubMed: 19363258]
- [324]. Exley C (2007). Organosilicon therapy in alzheimer's disease? *J Alzheimers Dis.* 11,301–2; discussion 3–4. [PubMed: 17851179]
- [325]. Yokel RA (1994). Aluminum chelation: Chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine. *J Toxicol Environ Health.* 41,131–74. [PubMed: 8301696]
- [326]. Qadir S, Jamshieed S, Rasool S, Ashraf M, Akram NA & Ahmad P (2014). Modulation of plant growth and metabolism in cadmium-enriched environments. *Rev Environ Contam Toxicol.* 229,51–88. [PubMed: 24515810]
- [327]. Huang B & Goldsbrough PB (1988). Cadmium tolerance in tobacco cell culture and its relevance to temperature stress. *Plant Cell Rep.* 7,119–22. [PubMed: 24241547]
- [328]. Zhang M, Mo H, Sun W, Guo Y & Li J (2016). Systematic isolation and characterization of cadmium tolerant genes in tobacco: A cdna library construction and screening approach. *PLoS One.* 11,e0161147. [PubMed: 27579677]
- [329]. Richter P, Faroon O & Pappas RS (2017). Cadmium and cadmium/zinc ratios and tobacco-related morbidities. *Int J Environ Res Public Health.* 14.
- [330]. Fransson MN, Barregard L, Sallsten G, Akerstrom M & Johanson G (2014). Physiologically-based toxicokinetic model for cadmium using markov-chain monte carlo analysis of concentrations in blood, urine, and kidney cortex from living kidney donors. *Toxicol Sci.* 141,365–76. [PubMed: 25015660]
- [331]. Satarug S (2018). Dietary cadmium intake and its effects on kidneys. *Toxics.* 6.
- [332]. Suwazono Y, Kido T, Nakagawa H, Nishijo M, Honda R, Kobayashi E, Dochi M & Nogawa K (2009). Biological half-life of cadmium in the urine of inhabitants after cessation of cadmium exposure. *Biomarkers.* 14,77–81. [PubMed: 19330585]
- [333]. Akesson A, Bjellerup P, Lundh T, Lidfeldt J, Nerbrand C, Samsioe G, Skerfving S & Vahter M (2006). Cadmium-induced effects on bone in a population-based study of women. *Environ Health Perspect.* 114,830–4. [PubMed: 16759980]
- [334]. Del Pino J, Zeballos G, Anadon MJ, Capo MA, Diaz MJ, Garcia J & Frejo MT (2014). Higher sensitivity to cadmium induced cell death of basal forebrain cholinergic neurons: A cholinesterase dependent mechanism. *Toxicology.* 325,151–9. [PubMed: 25201352]
- [335]. Tamir L (1980). Interrogatives in dialogue: Case study of mother and child 16–19 months. *J Psycholinguist Res.* 9,407–24. [PubMed: 7411493]
- [336]. Yuan Y, Jiang CY, Xu H, Sun Y, Hu FF, Bian JC, Liu XZ, Gu JH & Liu ZP (2013). Cadmium-induced apoptosis in primary rat cerebral cortical neurons culture is mediated by a calcium signaling pathway. *PLoS One.* 8,e64330. [PubMed: 23741317]
- [337]. Yuan Y, Zhang Y, Zhao S, Chen J, Yang J, Wang T, Zou H, Wang Y, Gu J, Liu X, Bian J & Liu Z (2018). Cadmium-induced apoptosis in neuronal cells is mediated by fas/fasL-mediated mitochondrial apoptotic signaling pathway. *Sci Rep.* 8,8837. [PubMed: 29891925]


- [338]. Wang B & Du Y (2013). Cadmium and its neurotoxic effects. *Oxid Med Cell Longev*. 2013,898034. [PubMed: 23997854]
- [339]. Chen L, Liu L & Huang S (2008). Cadmium activates the mitogen-activated protein kinase (mapk) pathway via induction of reactive oxygen species and inhibition of protein phosphatases 2a and 5. *Free Radic Biol Med*. 45,1035–44. [PubMed: 18703135]
- [340]. Xu B, Chen S, Luo Y, Chen Z, Liu L, Zhou H, Chen W, Shen T, Han X, Chen L & Huang S (2011). Calcium signaling is involved in cadmium-induced neuronal apoptosis via induction of reactive oxygen species and activation of mapk/mtor network. *PLoS One*. 6,e19052. [PubMed: 21544200]
- [341]. Min JY & Min KB (2016). Blood cadmium levels and alzheimer's disease mortality risk in older us adults. *Environ Health*. 15,69. [PubMed: 27301955]
- [342]. Peng Q, Bakulski KM, Nan B & Park SK (2017). Cadmium and alzheimer's disease mortality in u.S. Adults: Updated evidence with a urinary biomarker and extended follow-up time. *Environ Res*. 157,44–51. [PubMed: 28511080]
- [343]. Li X, Lv Y, Yu S, Zhao H & Yao L (2012). The effect of cadmium on abeta levels in app/ps1 transgenic mice. *Exp Ther Med*. 4,125–30. [PubMed: 23060935]
- [344]. Notarachille G, Arnesano F, Calo V & Meleleo D (2014). Heavy metals toxicity: Effect of cadmium ions on amyloid beta protein 1–42. Possible implications for alzheimer's disease. *Biomaterials*. 27,371–88. [PubMed: 24557150]
- [345]. Syme CD & Viles JH (2006). Solution 1h nmr investigation of zn<sup>2+</sup> and cd<sup>2+</sup> binding to amyloid-beta peptide (abeta) of alzheimer's disease. *Biochim Biophys Acta*. 1764,246–56. [PubMed: 16266835]
- [346]. Endres K & Fahrenholz F (2012). The role of the anti-amyloidogenic secretase adam10 in shedding the app-like proteins. *Curr Alzheimer Res*. 9,157–64. [PubMed: 21605036]
- [347]. Del Pino J, Zeballos G, Anadon MJ, Moyano P, Diaz MJ, Garcia JM & Frejo MT (2016). Cadmium-induced cell death of basal forebrain cholinergic neurons mediated by muscarinic m1 receptor blockade, increase in gsk-3beta enzyme, beta-amyloid and tau protein levels. *Arch Toxicol*. 90,1081–92. [PubMed: 26026611]
- [348]. Jiang LF, Yao TM, Zhu ZL, Wang C & Ji LN (2007). Impacts of cd(ii) on the conformation and self-aggregation of alzheimer's tau fragment corresponding to the third repeat of microtubule-binding domain. *Biochim Biophys Acta*. 1774,1414–21. [PubMed: 17920001]
- [349]. Del Pino J, Zeballos G, Anadon MJ, Diaz MJ, Moyano P, Diaz GG, Garcia J, Lobo M & Frejo MT (2016). Muscarinic m1 receptor partially modulates higher sensitivity to cadmium-induced cell death in primary basal forebrain cholinergic neurons: A cholinesterase variants dependent mechanism. *Toxicology*. 361–362,1–11.
- [350]. Medeiros R, Kitazawa M, Caccamo A, Baglietto-Vargas D, Estrada-Hernandez T, Cribbs DH, Fisher A & Laferla FM (2011). Loss of muscarinic m1 receptor exacerbates alzheimer's disease-like pathology and cognitive decline. *Am J Pathol*. 179,980–91. [PubMed: 21704011]
- [351]. Phuagkhaopong S, Ospondpant D, Kasemsuk T, Sibmooh N, Soodvilai S, Power C & Vivithanaporn P (2017). Cadmium-induced il-6 and il-8 expression and release from astrocytes are mediated by mapk and nf-kappab pathways. *Neurotoxicology*. 60,82–91. [PubMed: 28288823]
- [352]. Liu C, Cui G, Zhu M, Kang X & Guo H (2014). Neuroinflammation in alzheimer's disease: Chemokines produced by astrocytes and chemokine receptors. *Int J Clin Exp Pathol*. 7,8342–55. [PubMed: 25674199]
- [353]. Jiang JH, Ge G, Gao K, Pang Y, Chai RC, Jia XH, Kong JG & Yu AC (2015). Calcium signaling involvement in cadmium-induced astrocyte cytotoxicity and cell death through activation of mapk and pi3k/akt signaling pathways. *Neurochem Res*. 40,1929–44. [PubMed: 26248512]



**Figure 1 – Alzheimer's disease causes and risks.**

(Left panel) Rare mutations in *app*, *psen1*, and *psen2* alter APP processing and are known strong genetic causes of AD. Other variations in genes related to lipid metabolism, endocytosis and inflammatory responses, like *apoe*, *trem2* and *cd33*, are more common in the population but they confer moderate to low risk to AD. The environmental risks for AD include aging, cardiac and metabolic disorders (i.e., diabetes and hypertension), level of education, reduced social engagement and severe traumatic brain injury. (Right panel) Neuropathologically, AD is characterized by the formation of A $\beta$  plaques and NFTs in the brain. The production of A $\beta$  occurs due to aberrant processing of the APP, whereby it is cleaved by  $\beta$ - and  $\gamma$ -secretases, instead of  $\alpha$ -secretase. The A $\beta$  peptide is prone to misfolding and aggregation, leading to eventual oligomerization and formation of A $\beta$  plaques, which trigger a proinflammatory response from microglia and astrocytes. A $\beta$  also causes the hyperphosphorylation of tau, leading to its dissociation from microtubules and their eventual destabilization within neurons. Hyperphosphorylated tau is also prone to aggregation, forming NFTs, which correlates with neuronal loss and neurodegeneration.





**Figure 2 – The molecular composition of the body: essential and non-essential elements.** In human biology, the constituents of the body are classified into four groups according to their increasing complexity: atomic, molecular, cellular and tissue-system. In this system, the more complex components are built by combining the more basic ones. At the atomic level, only four of the 118 chemical elements currently known (*i.e.*, oxygen, carbon, hydrogen and nitrogen) are needed to make about 96% of the mass of the human body. Further 3.5% of body is composed of seven chemical elements, namely calcium, phosphorus, sulfur, potassium, sodium, chlorine and magnesium. The remaining constituents are trace elements. Of those, iron, zinc, manganese, copper, iodine, chromium, molybdenum, selenium and cobalt are considered essential nutrient elements for humans and are listed in order of recommended dietary allowance. Each of these elements has an optimal concentration in the body - too little or too much will result in reduced functionality or even death. In contrast, there are several non-essential elements likely to induce toxicity including


aluminum, lead and cadmium. Non-essential elements can cause cellular dysfunction at low concentrations, followed by death if they persist in biological systems.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 3 –. The impact of essential metals in AD.**

(Left panel) In the healthy brain essential metals such as iron, copper, zinc and manganese are kept at a homeostatic level to ensure optimal cellular functions. To achieve these conditions, a complex mechanism exist to tightly regulate its intracellular and extracellular concentrations. For instance, iron ( $\text{Fe}^{2+}$ ) is kept within cells bound to the iron storage protein ferritin, making it available upon cellular needs. In neurons, APP can oxidize  $\text{Fe}^{2+}$  into  $\text{Fe}^{3+}$  inducing its release into the extracellular matrix. Once outside the cell,  $\text{Fe}^{3+}$  rapidly binds to the iron mobilization protein, transferrin, making iron accessible for further biological processes. APP is also involved in the conversion of  $\text{Cu}^{2+}$  into  $\text{Cu}^+$ , favoring its removal from the brain. Zinc and manganese are also present in trace amounts which are finely regulated and essential to maintain brain function. (Right panel) In the AD brain, dyshomeostasis of essential metals seems to be linked with AD pathogenesis. Impairment of APP function, present in AD, can trigger an increased level of both intracellular and extracellular  $\text{Fe}^{2+}$  and  $\text{Cu}^{2+}$ , and a reduction of extracellular  $\text{Cu}^+$ , thus promoting its accumulation. Excessive  $\text{Fe}^{2+}$  and  $\text{Cu}^{2+}$  increases oxidative stress via production of ROS. In addition, iron, copper and zinc have higher binding affinity to A $\beta$  and can promote its


aggregation. Increased neuronal iron, copper and zinc also bind to tau protein and facilitate the formation of NFTs. Consequently, excessive amounts of heavy metals are found within plaques and NFT. Dyshomeostasis of essential metals in the extracellular space induce microglial and astrocytic activation, followed by the overproduction of proinflammatory cytokines such as, IL-1 $\beta$  and TNF- $\alpha$ .

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 4 –. The impact of non-essential metals in AD.**

The presence of non-essential metals such as lead, aluminum, and cadmium have neurotoxic effects on the brain which are exacerbated in AD. Lead exposure increases APP and BACE1 expression and disrupts microglial functioning, together increasing A $\beta$  production and plaque formation. Increased intracellular aluminum competes for the iron binding site in the iron-responsive element; as a result, Fe<sup>2+</sup> accumulates and increases the production of ROS. Aluminum also accumulates in NFT-bearing neurons. In addition, aluminum can bind to A $\beta$  and induce its aggregation. Cadmium also binds to A $\beta$  and involved in the formation of plaques. Heavy metal exposure induces microglial and astrocytic activation and subsequent increase in production of proinflammatory proteins, including IL-1 $\beta$ , IL-8, TNF- $\alpha$ , IL-6 and iNOS. *Extracellular levels:* changes in metal levels in the extracellular space include the metals accumulated in plaques, note that it might not necessarily reflect the number of free ions available in the extracellular space.